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resumo 
 
 
A Doença de Parkinson (DP) é a segunda doença neurodegenerativa 
progressiva mais comum e afeta profundamente o movimento. A DP é 
patologicamente caracterizada pela degeneração dos neurónios 
dopaminérgicos na substantia nigra pars compacta que leva a um 
decréscimo de dopamina no estriado. Apesar de pouco conhecida, a 
etiologia da DP parece envolver fatores genéticos e ambientais, 
correspondendo 10% dos casos a formas monogénicas da doença. 
Mutações na proteína DJ-1 têm sido relacionadas com a patogénese da 
doença e o interesse no estudo desta proteína tem vindo a crescer ao 
longo dos anos. Vários estudos mostram um envolvimento direto e 
indireto da DJ-1 nos mecanismos de neuroprotecção contra o stress 
oxidativo. Esta proteína foi encontrada em muitos tipos de células, 
incluindo neurónios e células da glia, com uma distribuição 
generalizada pelos diferentes compartimentos sub-celulares. Para além 
disso, a DJ-1 é secretada pelos astrócitos, mas o mecanismo pelo qual 
esta conferirá neuroproteção aos neurónios adjacentes é ainda 
desconhecido. Algumas das hipóteses que permanecem em aberto 
são: a internalização da DJ-1 oriunda dos astrócitos pelos neurónios 
para exercer os seus mecanismos de neuroprotecção no espaço 
intracelular; e a ativação de recetores membranares e de vias de 
sinalização celular. 
Este estudo pretende revelar algumas pistas sobre os mecanismos de 
neuroprotecção da DJ-1, usando uma proteína recombinante 
adicionada exogenamente a células SH-SY5Y. A proteína dimérica 
produzida revelou um efeito neuroprotetor em células SH-SY5Y sob 
condições de stress oxidativo. A adição desta proteína, em condições 
normais ou sob stress oxidativo, levou ainda à ativação das vias de 
sinalização Akt e ERK1/2. 
Neste estudo não se observou a internalização da DJ-1 em células SH-
SY5Y nem a sua interação com nenhuma proteína membranar, 
permanecendo por explicar o mecanismo neuroprotetor que a DJ-1 
secretada pelos astrócitos exerce nos neurónios. 
De forma a identificar possíveis interactores extracelulares, isto é, 
proteínas com as quais a DJ-1 interaja no espaço extracelular, foi feito 
um ensaio de ‘pull-down’ seguido de uma análise por cromatografia 
líquida acoplada a espectrometria de massa. Este primeiro ensaio 
permitiu a identificação de algumas proteínas interessantes, incluindo 
proteínas de adesão, proteínas envolvidas em processos celulares, 
como a orientação axonal, migração e proliferação celular, metabolismo 
dos carbohidratos, processos sinápticos e regulação positiva ou 
negativa de vias de sinalização celular. 
Os hipotéticos interactores deverão ser validados em estudos futuros, 
mas poderão ser uma ferramenta importante na compreensão dos 
mecanismos moleculares envolvidos na DP. 
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abstract 
 
Parkinson’s disease (PD) is the second most common progressive 
neurodegenerative disorder and profoundly affects movement. PD is 
pathologically characterized by the degeneration of the dopaminergic 
neurons in the substantia nigra pars compacta leading to loss of 
dopamine in the striatum. The etiology of PD is not well understood but 
seems to involve both genetic and environmental factors, and 10% of 
the cases correspond to monogenic forms of the disease. 
Mutations in DJ-1 protein have been linked to the pathogenesis of PD, 
with a growing interest in the study of this protein over the last years. 
Several studies have shown a direct and indirect involvement of this 
protein in neuroprotection mechanisms against oxidative stress insults. 
DJ-1 was found in different cell types, including neurons and glial cells, 
with a widespread sub-cellular distribution.  Furthermore, DJ-1 has also 
been shown to be secreted by astrocytes, but its neuroprotective role 
underlying this process is still not understood. Some hyposthesis of DJ-
1 neuroprotective mechanisms include triggering neuronal 
internalization of the protein and receptor-mediated activation of 
signalling pathways. 
This study intended to give some clues about these mechanisms 
possibly involved in neuroprotection by using a recombinant DJ-1 
exogenously added to SH-SY5Y cells. 
The dimeric produced protein had a neuroprotective effect in cultured 
SH-SY5Y cells under oxidative stress conditions. Moreover, although 
preliminary results, the exogenously addition of this protein, under 
normal or oxidative stress conditions, activated the Akt and the ERK1/2 
signaling pathways in the same cell line. 
On the other hand, there was no evidence for a DJ-1 uptake by the 
neuroblastoma cells, as there was also no evidence for any interaction 
of DJ-1 with membrane proteins, so DJ-1 must be exerting its 
neuroprotective effect outside of cells, probably not needing to be 
internalized by neurons after its secretion from astrocytes. 
In order to find some possible extracellular DJ-1 interactors a pull-down 
assay followed by LC-MS/MS analysis was performed. This preliminary 
approach allowed the identification of some interesting proteins, 
including cell adhesion proteins, proteins involved in cellular processes, 
such as, axon guidance, cell migration and proliferation, carbohydrate 
metabolism, synaptic process and positive or negative regulation of 
signalling pathways. 
The identified putative DJ-1 interactors must be validated, but can be an 
usefull tool to understand the molecular mechanisms that lead to PD. 
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1| INTRODUCTION 
1.1. PARKINSON’S DISEASE 
Parkinson’s disease (PD) is the second most common progressive 
neurodegenerative disorder (after Alzheimer’s disease) and profoundly affects 
movement [1-2]. This disease was first described in 1817 by James Parkinson in the 
classic ‘‘Essay on the Shaking Palsy’’ [3]. 
Parkinson’s disease is age-related and its prevalence, similar worldwide, is 
about 1% in people over the age of 60 and 4% over the age of 85 [4-5]. The onset of 
sporadic PD has a marked increase after the age of 60 [4]. Rare early-onset PD (EOPD) 
occurs before the age of 50, with an incidence of about 5%-10% of all cases, and has 
usually a monogenic origin [4]. EOPD can be divided in two groups: young-onset 
Parkinson's disease (YOPD), with an age of onset between 21 and 40 years, and 
juvenile-onset PD (JOPD), with onset before the age of 20 years [6]. 
The cardinal symptoms of PD (usually described as ‘‘parkinsonism’’) are resting 
tremor, bradykinesia, rigidity, and postural imbalance [1, 4]. Nevertheless, many non-
motor symptoms of PD, such as autonomic insufficiency, cognitive impairment, 
depression, olfactory deficits, psychosis, and sleep disturbance have been described 
[5]. Moreover, dementia affects about 40% of PD patients [7] and depression nearly 
50% [8]. 
Classical PD is characterized pathologically by degeneration of the 
dopaminergic neurons of the substantia nigra pars compacta (SNpc) leading to loss of 
dopamine (DA) in the striatum, in association with the appearance of Lewy bodies (LB) 
(Figure 1.1) and Lewy neurites in the surviving neurons [2, 9-10]. Lewy bodies are 
deposits of fibrils of insoluble polymers of α-synuclein in the cell body of neurons [11]. 
However, some monogenic forms of PD lack this typical LB pathology [12]. Clinical 
signs of PD are evident when approximately 80% of striatal dopamine and 50% of 
nigral neurons are lost [13]. 
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FIGURE 1.1| SUBSTANTIA NIGRA DEGENERATION IN PD WITH LEWY BODIES. The loss of SNpc neurons 
in advanced PD results in depigmentation of the SNpc (A), and in loss of the DA synthesising enzyme 
tyrosine-hydroxylase (TH) (B-C). The depositis of α-synuclein fibrils in the neuronal cell body are called 
Lewy bodies (D). Adapted from [11]. 
 
PD is multifactorial, likely arising from a combination of genetic susceptibility, 
ageing and gender (men are slightly more prone to PD [14]), environmental exposures, 
and gene-environment interactions [5, 15-16]. Many of the familial forms display 
clinical features that are considered atypical for PD, such as young onset, dystonia, or 
early occurrence of dementia [4]. 
The diagnosis of PD is based on clinical criteria, mainly parkinsonian symptoms 
and a definite diagnosis is only achieved by autopsy [2, 17]. Neuroimaging can be also 
helpful when patient’s history or clinical findings are atypical [17]. 
Oral levodopa (LD) therapy is still the most efficient symptomatic treatment of 
Parkinson’s disease and responsiveness to it has become a key diagnostic criterion [5, 
18 and references there in]. However, neuroprotective treatment that delays or 
arrests neurodegeneration in PD remains an unaccomplished goal, due to the lack of 
knowledge about the specific molecular events that provoke neurodegeneration in PD 
[19-20]. Until the late 90’s, most of the hypothesis of the etiology and pathogenesis of 
PD was postulated based on post-mortem tissue or neurotoxic animal models, such as 
using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as inductor of 
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dopaminergic degeneration [21]. These studies evidence three types of cellular 
dysfunction that seem to be important in PD pathogenesis: oxidative stress, 
mitochondrial respiration defect, and abnormal protein aggregation [20]. The 
knowledge about the disease only changed in 1997, when mutations in the gene 
encoding for α-synuclein [22], and then other PD-causing genes, were described as a 
cause of inherited PD [20]. 
 
1.1.1. ETIOLOGY OF PD 
The etiology of Parkinson’s disease is not well understood but seems to involve 
both genetic and environmental factors [2]. 
Environmental risks for PD include exposure to pesticides, rural living, drinking 
well water, heavy metal and solvent exposure, welding and mining [15]. In 1983, 
several people developed typical signs of PD after intravenous injection of drugs 
contaminated with MPTP. Subsequently, it was found that MPTP selectively damages 
dopaminergic cells in the substantia nigra [23] (Figure 1.2) favouring the hypothesis  
that exposure to environmental toxins might be related to the risk of PD. MPTP, as well 
as the herbicide paraquat and the pesticide rotenone, is a selective complex-I inhibitor 
and induce dopamine depletion in animal studies [24]. 
 
 
 
 
FIGURE 1.2| SCHEMATIC REPRESENTATION OF 
MPTP METABOLISM. After systemic administration, 
MPTP crosses the blood-brain barrier. Once in the 
brain, MPTP is converted to MPDP+ by MAO-B 
within nondopaminergic cells, such as glial cells, and 
then to MPP+ by an unknown mechanism. After 
that, MPP+ is released, again by an unknown 
mechanism, into the extracellular space. MPP+ is 
concentrated into dopaminergic neurons via the 
dopamine transporter (DAT). Adapted from [20]. 
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Many epidemiological studies have shown a reduced risk of PD among cigarette 
smokers [25-27].  Several mechanisms have been proposed to explain the potential 
neuroprotective effect of cigarette smoking. The most likely explanations involve 
nicotine, because nicotine may stimulate dopamine release, act as an antioxidant, or 
alter monoamine oxidase B activity [28]. Other possible protective factors include 
caffeine consumption and use of anti-inflammatory agents [29]. Nevertheless, the 
normal metabolism of DA can be a cause of neurodegeneration by generation of ROS 
(reactive oxygen species) [20, 30]. 
The majority of PD forms results from complex interactions among genes, and 
between genes and environmental factors [31]. The identification of distinct genetic 
loci at which pathogenic mutations are associated with parkinsonism (Table 1.1) 
contributes to the advance in the understanding of the mechanisms underlying PD 
pathogenesis [1]. Many pathogenic mutations produce variable pathological and 
clinical phenotypes distinct from typical PD (Table 1.1). 
 
TABLE 1.1| GENES AND LOCI ASSOCIATED WITH MONOGENIC PARKINSONISM [1, 31-32]. 
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1.1.2. MONOGENIC FORMS OF PD 
Although PD was long considered a non-genetic disorder of ‘sporadic’ origin, 5 
to 10% of patients are now known to have monogenic forms of the disease [4]. Several 
loci have been associated with both autosomal dominant [SNCA/PARK1/4 and Leucine-
rich repeat kinase 2 (LRRK2)/PARK8] and autosomal recessive PD [parkin/PARK2, PTEN-
induced kinase 1 (PINK1)/PARK6, DJ-1/PARK7, ATP13A2/PARK9] (Table 1.1) [1, 31-32]. 
Mutations in two other genes [vacuolar protein sorting 35 (VPS35) and eukaryotic 
translation initiation factor 4G1 (EIF4G1)], segregate in large families with dominant 
late-onset PD, but they are not assigned as PARK loci yet [33-34] (Table 1.1). 
Genome-wide association studies (GWAS) have been helpful to identify loci at 
which common genetic variants increase risk of developing apparently sporadic 
disease [1]. 
 
1.1.2.1. SNCA 
α-synuclein is a 140 kDa protein encoded by the SNCA [1] and is the major 
component of Lewy bodies [31]. SNCA is crucial to the pathophysiology of familial and 
sporadic PD [31]. 
Although rare, three missense mutations were identified in this gene: A53T, 
A30P and E46K (Figure 1.3). In the case of the A53T mutation, different studies showed 
that it leads to an early onset age (<50 years), rapid disease progression, atypical 
symptoms such as prominent cognitive deterioration, central hypoventilation, 
myoclonus and severe postural hypotention [12 and references there in]. The A30P 
mutation causes a typical PD phenotype with neuronal loss in the SNpc and LB 
pathology, and dementia late in the disease course [35]. The third SNCA missense 
mutation was described as leading to parkinsonism with Lewy bodies formation that 
progressed to dementia with visual hallucinations and fluctuations in consciousness 
[36]. 
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Numerous studies have also established a link between familial PD and 
duplications or triplications in the SNCA gene [37]. Indeed, multiplication of this gene 
appears to be a more common cause of PD than point mutations [12 and references 
there in]. Duplication of SNCA are associated with familial PD with a classical 
phenotype and an earlier onset age [38]. Gene triplication leads to earlier onset and 
faster progression of disease than duplication, indicating that disease severity is 
dependent on α-synuclein expression levels [1]. All these studies indicates that there is 
a relationship between α-synuclein expression levels and the appearance of PD [1]. 
 
1.1.2.2. LRRK2 
LRRK2 mutations are more frequently found in sporadic cases of PD than in 
autosomal dominant parkinsonism [31]. This gene encodes a leucine-rich repeat kinase 
2 (LRRK2), also called as Dardarin [39], that has been suggested to be involved in 
protein-protein interactions, maintenance of neurites, and regulation of neuronal 
survival [40]. This protein is expressed in the striatum, suggesting that LRRK2 
malfunction is relevant for PD pathogenesis [40]. Several mutations in LRRK2 have 
been described as segregating with PD in large families worldwide with autosomal 
dominant PD, such as Y1699C, I2020T, R1441C, and R1441G (Figure 1.4) [41]. However, 
the most common mutation in this gene is the G2019S mutation (Figure 1.4) which 
segregates with familial and sporadic PD [42]. 
Overall, mutations in LRRK2 are estimated to account for up to 10% of 
autosomal dominant familial PD cases and 0.6-1.6% of sporadic PD [43-44]. Patients 
 
FIGURE 1.3| α-SYNUCLEIN DOMAINS AND MISSENSE MUTATIONS: A53T, A30P AND E46K.  A number 
of imperfect KTKEGV repeat sequences (white stripes) are shown in the N-terminal region and central 
NAC (nonamyloid component) region.  Mutations that segregate with PD are annotated at their 
approximate position along the protein’s length. Adapted from  [1]. 
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with LRRK2 mutations typically have late disease onset and exhibit a wide range of 
pathologies that can differ between or within families [40]. 
 
 
FIGURE 1.4| LRRK2 DOMAINS AND PATHOGENIC MUTATIONS: Y1699C, I2020T, R1441C, R1441G, AND 
G2019S. Ank (ankyrin-like repeats), LRR (leucine-rich repeats), ROC (Ras of complex proteins) GTPase 
domain, COR (C-terminal of ROC), kinase, and WD40. Mutations that segregate with PD are annotated at 
their approximate position along the protein’s length. Adapted from [1]. 
 
1.1.2.3. PARKIN 
Parkin is an ubiquitin E3 ligase responsible for the addition of ubiquitin to 
specific substrates, targeting them for degradation by the proteasome or lysosome 
[45-46]. 
Parkin may play a role in sporadic PD through common and frequent mutations 
(Figure 1.5) [45]. Moreover, parkin is inactivated by nitrosative, dopaminergic, and 
oxidative stress, which indicates that loss of parkin function plays a role not only in 
sporadic forms of the disease but also in autosomal recessive parkinsonism [45]. 
Accumulation of parkin substrates is thought to contribute to DA neurodegeneration 
due to parkin inactivation in the pathogenesis of PD [1].  
 
 
FIGURE 1.5| PARKIN DOMAINS AND PATHOGENIC MUTATIONS. UBL (ubiquitin-like) and two RING 
domains separated by an IBR (in-between RING) domain. Mutations that segregate with PD are 
annotated at their approximate position along the protein’s length. Adapted from [1]. 
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PD-linked parkin mutations give rise to early-onset parkinsonism (10 to 15% of 
the cases), often with the absence of Lewy bodies, and account for a large proportion 
of the familial PD cases (for up to 50% of the cases) [45, 47]. 
 
1.1.2.4. PINK1 
The PINK1 protein is a putative serine/threonine kinase (PTEN-induced putative 
kinase-1) involved in mitochondrial response to cellular and oxidative stress [47]. In 
2009, Whitworth and Pallanck, suggest a mitochondrial quality-control pathway that 
fails in PD in which PINK1 and parkin are involved, leading to cellular dysfunction and 
death [48]. 
Mutations in PINK1 gene (Figure 1.6) were identified as a cause of autosomal 
recessive early-onset parkinsonism [47], with a prevalence below 4% [12 and 
references there in]. 
 
 
FIGURE 1.6| PINK1 DOMAINS AND PATHOGENIC MUTATIONS. MTS (mitochondrial targeting 
sequence), TM (putative transmembrane domain), and serine/threonine kinase Mutations that 
segregate with PD are annotated at their approximate position along the protein’s length. Adapted from 
[1]. 
 
1.1.2.5. ATP13A2 
ATP13A2 is a lysosomal membrane protein with an ATPase domain [49]. Loss-
of-function mutations in ATP13A2 gene underlying an autosomal recessive form of 
early-onset parkinsonism with pyramidal degeneration and dementia (Kufor-Rakeb 
syndrome) [49-50]. The unstable truncated mutant proteins were retained in the 
endoplasmic reticulum and degraded by the proteasome [49]. 
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1.1.2.6. DJ-1 
DJ-1 was first described as an oncogene [51], but nowadays the protein 
encoded by this gene is seen as a multifunctional protein. DJ-1 protein has been 
suggested to participate in response to oxidative stress and mutations in this protein 
lead to cell death, as observed in PD [52]. DJ-1 also seems to have chaperone activity in 
response to protein misfolding [53]. DJ-1-deficient mice show hypersensitivity to 
oxidative stress and DA neuron loss following treatment with MPTP, an oxidative 
stress-inducing compound [54]. DJ-1 was found to be responsive to hydrogen peroxide 
(H2O2) suggesting that it can act as a sensor for oxidative stress, for example, 
dopamine toxicity [55]. 
Despite the low frequency of pathogenic DJ-1 mutations in early-onset PD (DJ-1 
mutations seem not to contribute to the late-onset cases of PD), these mutations are 
the second most common known genetic cause of PD [56], being the age of onset 
before 40 years [56-57]. Two homozygous mutations in the DJ-1 gene have been 
shown to cause early-onset autosomal recessive Parkinson's disease in families in the 
Netherlands and Italy: a 14kb deletion removing exons 1 to 5 and a missense mutation 
(L166P) (Figure 1.7) [58]. The typical phenotype caused by these mutations is 
characterized by slow progression of the disease, good response to dopaminergic 
therapy, psychiatric disturbances, dystonic features, and clinical heterogeneity in 
disease severity [57]. 
 
FIGURE 1.7| DJ-1 GENE AND PATHOGENIC MUTATIONS. Mutations that segregate with PD are 
annotated at their approximate position along the protein’s length. Adapted from [1]. 
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1.1.3. PATHOGENESIS OF PD 
As stated above, toxicological studies of PD models and the knowledge of the 
function of genes involved in PD suggest two major hypotheses regarding the disease’s 
pathogenesis: protein misfolding and aggregation as a cause of SNpc dopaminergic 
neurons death, and the mitochondrial dysfunction with the consequent oxidative 
stress, including toxic oxidized DA species [20]. 
The protein deposition in brain tissues is a trait of age-related 
neurodegenerative disorders, like PD, suggesting that this fact is toxic to neurons [20]. 
Despite that, protein aggregation can be a defensive manner of the cell to remove 
toxic soluble misfolded proteins by inducing chaperones [59]. However, if chaperones 
are unable to properly refold proteins, they are target to proteosomal degradation by 
polyubiquitination [59]. On the other hand, the failure of the ubiquitine-proteosome 
system is a common pathway of neurodegeneration that underlies the development of 
familial and sporadic PD [60]. Even in sporadic PD, protein modifications, chaperones 
or proteosome dysfunction may lead to the accumulation of misfolded proteins, and 
the oxidative stress seems to have a key role in the pathogenesis of this form of 
disease too [20]. These facts are consistent with the genetic discoveries previously 
mentioned. 
As reported, several mutations can lead to neurodegeneration and 
development of PD pathogenesis (Figure 1.8). Moreover, misfolded proteins may 
contribute to PD neurodegeneration by overloading the ubiquitin proteasomal and 
lysosomal degradation pathways [61]. When proteins involved in these pathways are 
mutated (e.g. α-synuclein and parkin), the ability of the cell’s machinery to detect and 
degrade misfolded proteins is impaired [61]. Mutations in DJ-1 may alter its putative 
chaperone activity, leading to the accumulation of unwanted proteins and, 
consequently, to neurodegeneration [61]. Mitochondrial dysfunction and dopamine 
metabolism generate oxidative stress that can also promote protein misfolding and 
neurodegeneration [17, 61]. The reduced capacity of DJ-1 to detoxify ROS, may also 
originate oxidative stress in PD, and DJ-1 and PINK1 mutations can lead to 
mitochondrial dysfunction [61-62]. 
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FIGURE 1.8| GENETIC MUTATIONS AND THE PATHOGENESIS OF PD. Red arrows represent the 
targeting and delivery of damaged proteins for degradation. Dashed arrows correspond to unknown 
mechanisms. Blue arrows represent misfolded proteins [61]. 
 
More recent evidence in mammalian cells implicate parkin and PINK1 in the 
regulation of autophagy, with parkin being recruited from the cytosol to damaged 
mitochondria [63-64]. These events trigger mitochondria autophagy, when PINK1 is 
accumulated in this organelle [63-64]. Thus, mutations in parkin and PINK1 impaired 
this process, leading to the accumulation of defective mitochondria and, ultimately, 
neurodegeneration in Parkinson's disease [63-64]. Moreover, DJ-1 was also correlated 
with the PINK1/parkin pathway to control mitochondrial function and autophagy [62, 
65]. 
Thus, protein misfolding, mitochondrial dysfunction, oxidative stress, and 
autophagy are connected in the hypothetical pathogenic pathway of PD. The 
mechanisms of mitochondrial dysfunction and oxidative stress related to Parkinson’s 
disease have been extensively studied over the last years. 
 
1.1.3.1. MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS 
Mitochondria are ubiquitous organelles, critical for cell survival [66]. Their main 
function is to support aerobic respiration and to provide energy substrates for 
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intracellular metabolic pathways, but they are also involved in cell signalling, 
particularly in signalling for apoptotic cell death [66]. 
A dysfunction of mitochondrial energy metabolism leads to low levels of ATP 
production, impaired calcium buffering, and high levels of ROS generation [67]. It is 
known that the generation of ROS is related to aging and neurodegenerative disorders, 
including PD [67]. 
Several studies suggest that there is widespread oxidative damage in the brain 
of PD patients [68]. Evidence for mitochondrial metabolism impairment come from 
studies in autopsy and other tissue samples, and in vitro cell cultures derived from PD 
patients [69]. These studies revealed a decreased mitochondrial complex I activity in 
the substantia nigra [70] and in the frontal cortex [71]. The complex I deficiency in 
substantia nigra of PD patients supports the proposition that complex I deficiency may 
be directly involved in dopaminergic cell death in this disease [72].  
Further, loss of activity of complex I induced by neurotoxins, such as MPTP and 
rotenone, produces parkinsonism in humans and animals [23, 73-74]. The complex I 
inhibition causes an increased free radical generation and protein oxidation, and could 
contribute to oxidative damage that is involved in PD and other neurodegenerative 
disorders [66, 75]. On the other hand, free radicals can damage the respiratory chain, 
leading to further production of ROS [20, 66]. 
A complex I defect could also contribute to cell degeneration through 
decreased ATP synthesis and a bioenergetic deficit [68]. The reduction of the 
mitochondrial membrane potential impairs proton pumping, including complex I, 
leading to mitochondrial permeability, with the release of small mitochondrial proteins 
that engage apoptosis. Complex I inhibition can also decrease the activity of the 
energy-dependent proteasome, suggesting a possible mechanism by which the 
ubiquitin proteasomal system (UPS) might be impaired in sporadic PD [75]. The 
presence of ROS also increase the amount of misfolded proteins hindering the 
proteasome activity [20]. Several studies indicate that mitochondrial DNA (mtDNA) 
mutations could contribute to the impairment of the respiratory chain in PD, but in 
fact, no abnormality of this genome has been consistently identified in PD patients 
[76]. Nevertheless, studies in which mtDNA from PD patients is introduced into 
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mtDNA-depleted cells (cybrid studies) show reduced mitochondrial respiration [77-78], 
and the appearance of Lewy bodies and Lewy neurites in cybrid cells, linking the 
mtDNA expression to neuropathology [78]. 
Other proteins can also play a role on mitochondrial activity (and in other cell 
compartments), such as PINK1, parkin, α-synuclein, and DJ-1 [76]. PINK1 has an N-
terminal mitochondrial signal and an intramitochondrial location [76]. It was reported 
that loss of PINK1 results in mitochondrial dysfunctions in mice, reduced activities of 
complex I, complex II and aconitase [79]. Furthermore, PINK1 protects mitochondria 
from both intrinsic stress (e.g., dopamine metabolism and aging) and environmental 
insults (e.g., H2O2 and heat shock) [79]. This protective role of PINK1 in mitochondria 
might be explained by its involvement in the regulation of mitochondrial fission and 
fusion [79-80] or by the activation of mitochondrial chaperonin, such as TRAP1 and 
HtrA2 [81-82]. Moreover, parkin interplays dynamically with PINK1 in the regulation of 
mitochondrial morphology via mitochondrial fission/fusion [83-84]. 
Mutations in parkin result in a E3 ubiquitin ligase loss-of-function leading to the 
accumulation of parkin substrates within dopaminergic neurons, and consequently to 
nigral neuronal death [85]. Cells from parkin-knockout mice show an impaired 
aggresome (a specific cellular response to sequester potentially toxic misfolded 
proteins) formation [86], suggesting a direct involvement of parkin in the formation of 
Lewy bodies [46]. Mutations in parkin observed in PD patients were also suggested to 
prevent the formation of these protective inclusion bodies, possibly leading to the 
rapid onset and progression of the disease [46]. Parkin knockout mice revealed a 
decreased abundance of a number of proteins involved in mitochondrial function or 
oxidative stress, and reductions in respiratory capacity of striatal mitochondria [87]. In 
addition, parkin gene inactivation in mice leads to motor and cognitive deficits, and 
inhibition of amphetamine-induced dopamine release and glutamate 
neurotransmission [88]. 
α-synuclein is a predominantly cytosolic protein, but a fraction of it was 
identified in mitochondria membrane [89]. This binding of α-synuclein to the 
membrane of mitochondria could be related to its pathological role in mitochondrial 
dysfunction in PD [89]. α-synuclein inhibits complex I activity in a dose dependent 
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manner and is differentially expressed in mitochondria in different rat brain regions, 
suggesting that this protein might be important in neurodegeneration [90]. In addition, 
transgenic A53T mutant mice showed neuronal mitochondrial DNA damage and 
degeneration, and consequently mitochondrial structure and function abnormalities 
[91]. 
DJ-1 was found in cytosol, nucleus, microsomes (endoplasmic reticulum [ER] 
and Golgi), and in mitochondria (in mitochondrial matrix and inter-membrane space) 
[92-94]. Under oxidative stress conditions, DJ-1 translocates from the cytoplasm to 
mitochondria and nucleus, possibly to exert its protective role against oxidative stress 
[95-96]. It was reported that DJ-1 is important in the maintenance of the mitochondrial 
complex I activity [97]. Additionally, DJ-1 acts as an oxidative stress sensor within cells 
[11, 98], and DJ-1-deficient cells display an increased sensitivity to oxidative stress, 
leading to increased apoptosis due to the high levels of ROS [99-100], and proteasomal 
inhibition [100]. DJ-1 functions as a redox-sensitive molecular chaperone and inhibits 
α-synuclein aggregate formation [101-102].  
The inhibition of DJ-1α in flies, a Drosophila homologue of human DJ-1, causes 
accumulation of ROS, hypersensitivity to oxidative stress, and dysfunction and 
degeneration of dopaminergic and photoreceptor neurons [103]. In DJ-1 null mice, 
nigrostriatal dopaminergic function is altered and motor deficits are present [104]. 
As previously mentioned, the DA metabolism produces ROS, such as hydrogen 
and superoxide radicals, and auto-oxidation of DA produces DA-quinone, a molecule 
that damages proteins by reacting with cysteine residues [20]. 
All together, these evidence show the importance of mitochondria and 
oxidative stress in the pathogenesis of PD. 
 
1.2. ROLE OF DJ-1 IN NEUROPROTECTION 
The DJ-1 gene encodes a 189 amino acid protein with ≈20kDa and multiple 
putative functions [105, 106 and references there in]. DJ-1 has attracted attention 
because of its involvement in certain cases of familial early onset Parkinson’s disease 
[57, 107-108]. A homozygous deletion, missense mutations (L166P, M26I), and a 
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compound heterozygous mutation in DJ-1 gene have been reported to be directly 
related to EOPD, and loss or reduction of DJ-1 protein function has been considered to 
cause this phenotype [56, 58, 109]. DJ-1 is a member of the ThiJ/PfpI superfamily, and 
has homologues in most (if not all) organisms [107]. 
As mentioned above, DJ-1 was originally identified as a novel oncogene in 
collaboration with active ras [51], related to fertilization [110], and later found to be a 
PD causative gene [58]. Additionally, many functions have been attributed to DJ-1, 
including transcriptional regulation [111], molecular chaperone [102, 112], 
peroxiredoxin-like peroxidase activity [113], modulator of autophagy and 
mitochondrial quality control [114-116], oxidative stress modulation [52], and 
important roles in the activation of pro-survival [103, 117-120] and inhibition of pro-
apoptotic pathways [121-123].  
In addition to a cytosolic localization, DJ-1 is also localized in the mitochondrial 
matrix and inter-cellular space of neurons. DJ-1 has a widespread distribution in the 
brain and peripheral tissues [93, 106], unlike parkin and α-synuclein, which have a 
more restricted tissue distribution [93]. Nevertheless, neurodegeneration associated 
with DJ-1 mutations remains mainly confined to the substantia nigra [106]. DJ-1 is 
expressed in neurons (dendritic, cytoplasmic, and nuclear distribution) of different 
neurotransmitter phenotypes and in all glial cell types: astrocytes, microglia and 
oligodendrocytes [106, 124]. The localization of DJ-1 in mitochondria suggests that it 
may play important roles in mitochondrial function [93]. As stated above, it was 
reported that upon an oxidative insult, more DJ-1 translocates to mitochondria [95], 
which could be related to a neuroprotective role of the protein. 
DJ-1 protects neurons against oxidative stress-induced cell death and loss of DJ-
1 may lead to Parkinson’s disease by conferring hypersensitivity to dopaminergic 
insults [52, 54, 103, 125]. Moreover, mitochondria isolated from DJ-1 deficient mice 
produce more ROS compared with control animals [115]. All these findings suggest 
that DJ-1 has an antioxidant activity or can act as a free radical scavenger. 
Nevertheless, DJ-1 seems to be a weaker free radical scavenger when compared with 
peroxidases, hence its antioxidant activity might be due to other additional indirect 
activities of the protein [103, 113]. For example, DJ-1 has been described to up-
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regulate the antioxidant glutathione synthesis [126] and to stabilize the transcription 
factor Nrf2, a major regulator of antioxidant genes [127]. 
In addition, DJ-1 deficiency in cell lines, cultured neurons, mouse brain and 
lymphoblast cells derived from PD patients showed abnormal mitochondrial 
morphology [115]. This phenotype contributes to the oxidative stress sensitivity 
caused by DJ-1 loss, which can be rescued by the expression of Pink1 and parkin [115]. 
Moreover, DJ-1 deficiency leads to altered autophagy in murine and human cells [115], 
and it has been implicated in mitochondrial quality control [114, 116]. 
In 2003, Yokota and colleagues demonstrated that downregulation of 
endogenous DJ-1 increases neuronal cell death, induced by H2O2, and neurons were 
rescued by overexpression of wild-type (WT) DJ-1 but not by the L166P mutant DJ-1 
[125]. Again, this finding suggests that DJ-1 has antioxidant activity and this mutation 
(which causes a loss of function) consequently can be responsible for neuronal cell 
death in PD patients [125]. In the same study, it was shown that down regulation of 
endogenous DJ-1 enhanced ER-stress and proteasome inhibition, and its 
overexpression slightly suppresses these mechanisms [125]. 
An important finding from crystallography studies is that DJ-1 exists as an 
homodimer [112, 128-129]. The L166P mutation appears to disrupt the C-terminal 
domain and the dimerization capability, suggesting that the dimerization is functionally 
important [112, 128-129]. On the other hand, Baulac and colleagues, showed that this 
mutated DJ-1 does not prevent dimer formation, but apparently, forms oligomers or 
higher molecular weight structures (analogous to aggregates) [106]. These 
observations can be related to the aggregation of several proteins into insoluble 
intracellular inclusions (Lewy bodies) implicated in neurodegenerative diseases, 
including PD [106]. Some of these proteins are α-synuclein and parkin [130-131], and 
apparently, DJ-1 is not a major component of Lewy bodies [132]. However, it was 
shown that DJ-1 is present in Tau inclusions from tauopathies disorder cases, 
suggesting that abnormal DJ-1 aggregation is implicated in neurodegenerative disease 
mechanisms [133]. Another group reported the presence of DJ-1 in a large molecular 
complex, and provided evidence for an interaction between endogenous DJ-1 and α-
synuclein [134]. It was also demonstrated that DJ-1 can act as a redox-sensitive 
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chaperone protein which can increase the solubility of α-synuclein, preventing its 
aggregation [102]. α-synuclein is also mutated in forms of inherited parkinsonism [35-
36], so its interaction with DJ-1 may play an important role in PD [134]. Nevertheless, 
this interaction does not seem to be direct, and there are candidate proteins to anchor 
α-synuclein and DJ-1 such as mortalin, nucleolin, calnexin, grp94, and clathrin [135]. 
Still regarding the L166P mutation of DJ-1, it was also shown that this mutant is 
polyubiquitinated or binds to polyubiquitinated proteins [106, 136]. Moreover, several 
groups have found that the L166P mutation reduces protein stability, being quickly 
degraded through the proteasome [92, 108, 136-137], although proteasomal 
degradation may be only one of the mechanisms for DJ-1 turnover [137]. On the other 
hand, M26I mutated protein is as stable as WT DJ-1, has normal expression levels, and 
is not polyubiquitinated [106]. Another interesting feature of this mutated form is the 
ability to self-interact and to form homo-oligomers [108]. The DJ-1 mutant E64D was 
found to have a similar half-life, structure and dimer formation capacity compared to 
WT DJ-1 and was not subjected to accelerated proteasomal degradation, however the 
structure rigidity of the mutated protein seems to be higher than WT protein [137]. 
Another important structural aminoacid of DJ-1 is the cysteine-106 (C106), 
which is a highly conserved residue located at the ‘‘nucleophile elbow’’ region (Figure 
1.9), extremely sensitive to radiation, which suggests that it may also be a favoured 
target of modification by ROS generated by oxidative stress [128]. It was reported that 
under oxidative conditions, the C106 residue of DJ-1 was oxidized, whereas C46 and 
C53 remained in their reduced state [98]. It was reported that DJ-1 may be activated 
by a complex mechanism dependent on its redox center C106 and modulated by the 
peripheral cysteine residues, and that impairment of oxidative-induced activation of 
DJ-1 might contribute to the pathogenesis of PD (Figure 1.10) [123]. Furthermore, 
inhibition of mitochondrial complex I is abolished by overexpression of WT DJ-1, but 
not by the C106 DJ-1 mutant [98]. Moreover, studies with a variant of C106, where the 
cystein residue was substituted by an alanine residue, showed resistance to oxidation 
of the protein and incapacity to localize in mitochondria under oxidative stress 
conditions, suggesting that cysteine mutations might affect the ability of DJ-1 to 
protect against cell death [98]. Another report indicates that C106 oxidation is crucial 
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for the protection of cells from mitochondrial damage by DJ-1 [111]. Taken together, 
these findings suggest that C106 may be a site of regulation of DJ-1 activity by 
oxidation, making the protein a potential sensor of oxidative stress [98, 128]. 
 
 
 
FIGURE 1.9| DJ-1 MONOMER STRUCTURE. Representation of DJ-1 monomer, with residues Glu-18, Cys-
106, and His-126 in yellow (a). The Leu-166 residue in red is mutated to proline in PARK7 familial PD. A 
closer view of the “nucleophile elbow” region (b). Adapted from [128]. 
 
 
The C106 residue has been indicated to facilitate secretion of DJ-1 through 
cellular membrane microdomains in cultured cells [138]. This study also showed that 
DJ-1 was detected in the culture media of all types of cells examined (human SH-SY5Y 
and HeLa cells, and mouse Flp-In™ NIH3T3 cells) [138]. In the same study it was shown 
that DJ-1 was located in microdomains containing caveolin, and the treatment of cells 
with an inhibitor of non-classical pathways suggests that a portion of DJ-1 is secreted 
through microdomains [138]. Another evidence of this work is that oxidation of DJ-1 at 
C106 seems to facilitate its secretion [138]. 
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FIGURE 1.10| SCHEMATIC REPRESENTATION OF PROPOSED DJ-1 ACTIVATION STATES. The surface 
contour plot of the DJ-1 dimer (lower left) shows the cysteine side chains of each monomer (green 
residues belong to the yellow homomer, blue residues to the purple monomer). The Cys-53 side chains 
are prominently localized at the edge of the dimer interface. The Cys-106 residues are deeply buried 
within each DJ-1 monomer, necessitating a channel for ROS to enter the central active site Cys-106 (Cc). 
A peripheral (Cp) redox center that appears to comprise Cys-53 and perhaps other oxidizable and/or 
structural residues (Cys-46 and Met-26) could gate the accessibility of reactive oxygen species to Cys-
106 and activate the central site (Cc*). Peripheral redox center mutants might be sensitized due to 
deregulated gating of reactive oxygen species, allowing unquenched access to the active center. 
Alternatively, Cp might function as “resolving cysteines,” reducing transiently formed mixed disulfide 
bonds of Cys-106 with effector proteins. Formation of Cc* might “open” the DJ-1 conformation, 
allowing access of the buried Cys-106 to cysteines of other proteins [123]. 
 
In PD brain tissues, DJ-1 is expressed in reactive astrocytes at high levels, 
whereas non-disease astrocytes express this protein at very low levels, and this 
expression is sensitive to oxidative stress conditions [132-133]. Yanagida and 
colleagues showed that oxidative stress induces the release of DJ-1 protein from 
astrocytes, which may contribute to astrocyte-mediated neuroprotection [139]. In fact, 
DJ-1 knock-down in astrocytes impaired the astrocyte-mediated neuroprotection 
against rotenone, and its overexpression enhances their capacity to protect neurons 
[140-141]. Recently, DJ-1 deficiency was also found to impair astrocyte mitochondrial 
physiology [142]. On the other hand, a recombinant GST-DJ-1 has been shown to be 
incorporated into cells when it was injected into the substantia nigra of rats with 
neurodegeneration induced by 6-OHDA (6-hydroxydopamine) with a protective effect, 
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even when the administration was post-treatment [143]. In the same study, the uptake 
of recombinant DJ-1 was demonstrated (in the presence or absence of oxidative stress 
stimuli) as well as the inhibition of ROS production and cell death of SH-SY5Y cells after 
treatment with 6-OHDA [143]. This incorporation of recombinant DJ-1 was not seen in 
L166P mutant DJ-1 [143], maybe due to its instability and/or insoluble form [144-145]. 
DJ-1 has also been observed in serum, plasma and cerebrospinal fluid of PD patients 
[146-148]. All these findings suggest that DJ-1 shuttles between the inside and outside 
of cells [138]. However, some questions remain to be answered: 
- If DJ-1 enter into neurons, which mechanisms are responsible for DJ-1 
internalization? 
- Is there any DJ-1 specific membrane receptor? 
- Are there extracellular proteins interacting with DJ-1? 
- Are these mechanisms involved in neuroprotection? 
- Does DJ-1 act only as an extracellular first-line defence of ROS? 
In order to address the DJ-1 entry mechanisms into neurons, it is necessary to 
understand the uptake processes of macromolecules through the cellular membrane. 
 
1.3. PROTEIN INTERNALIZATION MECHANISMS 
The cell membrane allows the communication between the cytoplasm and the 
extracellular environment by regulating the entry and exit of molecules from cells 
[149]. Macromolecules must be packed into membrane vesicles derived by the 
invagination of the plasma membrane in a process termed endocytosis [149]. 
Endocytosis has an important role in development, immune response, 
neurotransmission, intracellular communication, signal transduction, and cellular and 
organismal homeostasis [149]. Endocytosis occurs by multiple mechanisms that can be 
divided in two broad categories: phagocytosis, which is the uptake of large particles, 
and pinocytosis, the uptake of fluid and solutes (Figure 1.11) [149]. Phagocytosis is 
typically performed by specialized mammalian cells, whereas pinocytosis occurs in all 
cells in general [149]. Pinocytosis may occur by at least four mechanisms: 
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macropinocytosis, clathrin-mediated endocytosis (CME), caveolin-mediated 
endocytosis, and clathrin- and caveolin-independent endocytosis (Figure 1.11) [149]. 
 
FIGURE 1.11| MULTIPLE PORTALS OF ENTRY INTO THE MAMMALIAN CELL. The endocytic pathways 
differ in the size of the endocytic vesicle, the nature of the cargo (ligands, receptors and lipids) and the 
vesicle formation mechanism [149]. 
 
Caveolae mediate the transport of serum proteins from the bloodstream to 
tissues across the endothelial cell layer [149]. Calveolae are present in many cells, and 
bound cholesterol and sphingolipid-rich microdomains of the plasma membrane, 
where various signalling molecules and membrane transporters are present [149-150]. 
Caveolin, a dimeric protein that binds cholesterol, is responsible for the shape and 
structural organization of caveolae [149] that typically appear as rounded plasma 
membrane invaginations of 50-80 nm in diameter [151]. Caveolae-mediated 
endocytosis seems to be highly regulated by the cargo molecules [149]. Although, the 
molecular basis of the cargo molecules and caveolae-localized receptors remain to be 
clarified [149]. 
Rafts are other type of cholesterol-rich microdomains on the plasma membrane 
that have 40-50 nm in diameter and diffuse freely on the cell surface [152-153]. Most 
probably these small rafts are captured and internalized by an endocytic vesicle, such 
as clathrin-coated vesicles (CCVs) [149, 154], or through a clathrin- and caveolin- 
independent manner [149, 155]. In neurons and neuroendocrine cells, clathrin-
dependent mechanisms are crucial to the normal synaptic activity, but there are also 
clathrin-independent mechanisms of endocytosis that rapidly makes the recovery of 
membrane proteins after stimulated secretion [149, 156]. The caveolae- and clathrin-
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independent endocytosis mechanisms remain poorly understood, whereas the 
molecular mechanisms of CME are better understood [149]. 
CME occurs constitutively in all mammalian cells and is responsible for the 
continuous uptake of essential nutrients [149]. This mechanism is fundamental for 
intercellular communication during development [157], and during the organism’s life 
as it modulates the signal transduction by controlling the levels of surface signalling 
receptors, and by mediating the rapid clearance and downregulation of activated 
signalling receptors [149]. The assembly of CCVs under physiological conditions 
requires assembly proteins (APs) and numerous accessory proteins, such as dynamin, 
AP-2, and Eps15, which have been implicated in CME [149, 158]. Clathrin-coated 
vesicles mediate the sorting and selective transport of membrane-bound proteins, the 
endocytosis of transmembrane receptors, and the transport of newly synthesized 
lysosomal hydrolases from the trans-Golgi to the lysosomes [159]. CME occurs in 
endocytic “hotspots” in the plasma membrane that are constrained by the actin 
cytoskeleton [160], despite that, actin assembly doesn’t seem to play an obligatory 
role in endocytic coated vesicle formation [161]. 
 
1.4. EXTRACELLULAR INTERACTOME 
The study of cellular membrane or inter-cellular proteins interactome may 
contribute to understand the mechanisms of action of proteins released from cells 
possibly involved in protecting cells against oxidative stress conditions [139]. In fact, 
there is evidence for DJ-1-mediated neuroprotection involving DJ-1 downstream 
molecules through DJ-1 expressed by astrocytes [140]. Thus, the study of extracellular 
or cellular membrane interactors is fundamental to the knowledge about the 
neuroprotective mechanisms mediated by DJ-1 expressed and secreted by astrocytes. 
In order to identify specific interactors in the cellular membrane, as specific 
receptors, or in the inter-cellular space of cells, crosslinking strategies can be used to 
link a protein of interest to interacting proteins in a stable form [162-163]. Another 
possibility is the pull-down of proteins contained in conditioned medium by using 
immunopurification or tag-affinity strategies. 
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1.5. OBJECTIVES 
As stated above, DJ-1 plays an important role in neuroprotection mechanisms, 
such as those observed in oxidative stress conditions. Moreover, the protein is 
expressed in neurons and astrocytes, and its release from astrocytes is enhanced in 
oxidative stress conditions [139]. So, DJ-1 secretion by astrocytes [139] may further 
play a neuroprotective role in target neurons, with evidence for its uptake by SH-SY5Y 
cells [143]. Although several mechanisms of protein internalization can be used, none 
have been associated with DJ-1 neuronal internalization. Furthermore, no membrane 
receptor or extracellular interactors that can be related to DJ-1-mediated 
neuroprotection have been identified yet. 
This study intends to provide some insight about the neuroprotective 
mechanisms of the exogenously added DJ-1. The study of these mechanisms will 
further elucidate how the protein shuttles between cells and how astrocytes can 
promote neuronal rescue under oxidative stress conditions. 
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2| METHODS 
2.1. RECOMBINANT DJ-1 PRODUCTION 
2.1.1. DJ-1 CLONING 
The synthetic DNA coding for the human protein DJ-1 with the codons 
optimized for E. coli expression was obtained from GeneArt® (Invitrogen) and it was 
amplified by polymerase chain reactions (PCR) using the following primers: forward 
primer: GCTAGCAAACGTGCACTGGTTATTCTG and reverse primer: 
CTCGAGTCAATCTTTCAGAACCAGCGGTG. The forward and reverse primers introduced a 
Nhe I and Xho I sites respectively at the ends of the amplified sequence (restriction 
sites are represented in bold and the STOP codon is underlined). 
The PCR was performed in a volume of 100 μl, in the presence of 50 ng of 
template DNA, 100 pmoles of forward and reverse primers, and 5 Units of 
recombinant Taq DNA polymerase (GE Healthcare), 10 nmoles of dNTP’s, and the PCR 
was performed using the following cycling parameters: a first step of 5 min at 95 °C, 
followed by 35 cycles of 30 sec at 95 °C, 30 sec at 57 °C, and 1 min at 72 °C. After 
confirming the size of the amplified product by an agarose gel electrophoresis, the 
DNA band of the corresponding product was purified using the NZYGelpure gel 
extraction kit from NZYTech. The purified product was bound to pGEM®-T-easy vector 
system (Promega) according to the manufacture’s protocol and the resultant 
construction was transformed in TOP10F´ competent cells (Invitrogen) that were then 
plated in  9 cm (diameter) Petri dishes with Luria-Bertani (LB) agar medium 
supplemented with 50 μg/ml ampicillin, 4 μmoles of isopropyl β-D-1-
thiogalactopyranoside (IPTG), and 3 μmoles of 5-bromo-4-chloro-3-indolyl-beta-D-
galacto-pyranoside (X-Gal) for blue/white colony selection. White colonies were picked 
and grown in liquid LB supplemented with 50 μg/ml ampicilin, and the DNA was 
isolated using the High Pure Plasmid Isolation Kit from Roche. 
The subcloning of the DJ-1 coding DNA from pGEM-T-Easy vector to pSKB-3 
vector (DJ-1_pSKB-3) was performed by digesting 1 μg of each pGEM-T-Easy 
construction and pSKB-3 with 2.5 Units of both Nhe I and Xho I (New England Biolabs, 
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Inc.), in buffer 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium 
acetate, 1 mM ditiothreitol, pH 7.9, supplemented with 0.1 mg/ml Bovine Serum 
Albumin followed by agarose gel electrophoresis, where the correct size bands were 
cut, purified with NZYGelpure gel extraction kit (NZYTech) and the digested DNA 
fragments were ligated using T4 DNA Ligase (New England Biolabs, Inc.), according to 
the manufacturer’s instructions. The ligated DNA molecules were then used to 
transform NZYStar competent cells (NZYTech), that were grown at 37 °C in LB/agar 
plates supplemented with kanamycin (50 μg/ml) and tetracycline (15 μg/ml). Two 
colonies were picked and grown in liquid LB supplemented with kanamycin (50 μg/ml), 
the DNA was isolated using the High Pure Plasmid Isolation Kit (Roche) and the DNA 
sequence was confirmed by Sanger DNA Sequencing at STAB Vida. 
 
2.1.2. DJ-1 EXPRESSION 
The DJ-1_pSKB-3 construct (Figure 2.1) was transformed into competent E. coli 
BL21star (DE3) strain and plated into LB/agar supplemented with 50 μg/ml kanamycin. 
One colony was used to inoculate 100 ml of LB supplemented with 50 μg/ml 
kanamycin sulphate that was grown overnight at 37 °C, from where 25 ml were used 
to inoculate 1 L of LB supplemented with 50 μg/ml kanamycin. The cells were allowed 
to grow at 37 °C with shaking. When the optical density at 600 nm reached 0.5, the 
temperature of the incubator was decreased to 18 °C and one hour later the protein 
expression was induced by the addition of IPTG to a final concentration of 1 mM. The 
protein expression was allowed to occur for another 16 hours. 
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FIGURE 2.1| MAP OF THE CONSTRUCT OF DJ-1_PSKB-3. Representation of the DJ-1_pSKB-3 construct 
which contains: lac I – lac repressor gene; His Tag – hexahistidine tag; TEV – tobaco etch virus protease 
recognition site; kan – kanamycin resistance gene; the DJ-1 cDNA (optimized for E. coli expression) 
cloned between Nhe I and Xho I restriction endonuclease sites. The vector pSKB-3 corresponds to pET-
28a where thrombin recognition site was modified to TEV recognition site. 
 
2.1.3. DJ-1 PURIFICATION 
The cell suspension was centrifuged (20 min, 9,000×g, 4 °C), the cellular pellet 
was suspended in 50 ml of 20 mM sodium phosphate, 500 mM NaCl, 10 mM Imidazole, 
pH 7.2, and disrupted through a high pressure homogenizer EmulsiFlex-C3 (AVESTIN), 
with 3 passages at 1000 bar. The cellular extract was clarified by centrifugation (20 
min, 9,000×g, 4 °C), the supernatant was filtered through 0.2 μm syringe filters and the 
protein was applied to a 5 ml HisTrap HP column (GE Healthcare) using a Bio-Rad 
BioLogic LP (Bio-Rad) low-pressure chromatography system. After column loading, the 
column was extensively washed with loading buffer (20 mM sodium phosphate, 500 
mM NaCl, 10 mM Imidazole, pH 7.2) and protein elution was obtained by stepwise 
increasing of imidazole concentration up to 500 mM. 
The eluted fractions containing DJ-1 were quantified by using the 2-D Quant Kit 
(GE Healthcare) and analysed by Coomasie Brilliant Blue R-250 and silver stained SDS-
PAGE [4-20% polyacrylamide gel (Bio-Rad)]. The fraction which contained the highest 
amount of DJ-1 was dialysed [dialysis membrane with cut-off of 12-14,000 Da 
(Medicell International Ltd)] against PBS (8 mM K2HPO4, 2 mM NaH2PO4·H2O, 150 mM 
NaCl), quantified by measuring absorption at 280 nm using a Nanodrop ND-1000 
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Spectrophotometer (Thermo Fisher Scientific) and stored at -80 °C in PBS with 10 % 
glycerol. 
 
2.1.4. GEL BAND PROCESSING 
Bands from the gel used to analyse the eluted fractions were excised, sliced in 
small pieces, and transfered to microcentrifuge tubes with 1 mL of de-ionized water 
(to prevent gel bands dehydration). Gel slices were then destained by removing water 
and adding 1 mL of destaining solution (50 mM ammonium bicarbonate and 30% 
acetonitrile). The destaining step was performed in a thermomixer (comfort, 
Eppendorf) at 850 rpm for 15 min. The destaining solution was removed, and the 
process was repeated if the gel pieces remained blue. Otherwise 1mL of water was 
added and the tubes were shaken in the thermomixer at 850 rpm for 10 minutes. After 
this washing step, the water was removed and the gel bands were dehydrated on 
Concentrador Plus (Eppendorf) for 1 hour at 60 °C. Then, enough volume of trypsin (15 
ng/μL in 10 mM ammonium bicarbonate) was added to cover the dried gel bands and 
incubated for 10 minutes, on ice, in order to rehydrate the gel. After this period, 10 
mM ammonium bicarbonate was added to cover gel bands again, and incubated 
overnight at room temperature in the dark to perform the in-gel digestion. The tryptic 
solution (containing trypsin and peptides) was collected to low binding microcentrifuge 
tubes (Eppendorf) and the remaining peptides were sequentially extracted from gel 
pieces by adding 40 μL of 30%, 50%, and 98% of acetonitrile (ACN) in 1% formic acid 
(FA), with agitation in the thermomixer at 1050 rpm for 15 min. Each solution was 
collected to the tube containing the initial tryptic solution. Peptides mixtures were 
concentrated by rotary evaporation, using the Concentrator Plus at 60 °C, and 
resuspended to 100 μL in a solution of 5% FA. Peptides were desalted using C18 Bond 
Elut OMIX tips (Agilent technology). Briefly, tip columns were hydrated with 30 μL of 
90% ACN and 5% of FA and equilibrated with 180 μL of 5% FA. Peptides were loaded to 
the columns and this step was repeated twice, followed by a washing step with 60 μL 
of 5% FA solution and elution to new tubes with 120 μL of 90 % ACN and 5% of FA. 
Eluates were concentrated using the Concentrator Plus at 60 °C.  Sample volume was 
adjusted to 30 μL in a solution of 2 % ACN and 0.1 % FA and transferred into vials for 
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posterior Liquid Chromatography coupled to tandem mass spectrometry (LC-MS/MS) 
analysis. 
 
2.1.5. PROTEIN IDENTIFICATION BY LC-MS/MS 
Peptides were resolved by liquid chromatography (nanoLC Ultra 2D, Eksigent) 
on a ChromXPTM C18 reverse phase column (300 μm ID × 15cm length, 3 μm particles, 
120 Å pore size, Eksigent) at 5μL/min. Peptides were eluted into the mass 
spectrometer with an acetonitrile gradient in 0.1% FA (5% to 98% ACN, in a multiple 
step gradient for 25 min), using an electrospray ionization source (DuoSpray™ Source, 
ABSciex). The mass spectrometer (Triple TOF™ 5600 System; ABSciex)  was 
programmed for information dependent acquisition (IDA) scanning full spectra (350-
1250 m/z), followed by 20 MS/MS on multiple charged ions (+2 to +5) and performed 
one MS/MS before adding those ions to the exclusion list for 15 s (mass spectrometer 
operated by Analyst® TF 1.5.1, ABSciex).  
Peptide identification was performed using Protein Pilot software (v4.5, 
ABSciex). Search parameters used were the following: SwissProt database, against 
Homo sapiens, E. coli and all species, and the recombinant protein sequence database, 
trypsin digestion, acrylamide as cysteine alkylating reagent, special factor gel-based ID, 
thorough ID search effort, and 0.05 Unused ProtScore (10% confidence score) as 
detected protein threshold. Data analysis was based on an independent False 
Discovery Rate analysis (FDR) using the target-decoy approach. Positive identifications 
were considered when proteins present 95% confidence (5% local FDR) with more than 
one peptide hit with individual confidence above 95% or with a single peptide hit with 
an individual confidence above 95% and a minimum sequence tag of 3 amino acids (4 
consecutive peaks in the MS/MS spectrum). 
 
2.1.6. HPLC-SIZE EXCLUSION CHROMATOGRAPHY 
High-performance liquid chromatography (HPLC)-size exclusion 
chromatography (SEC) was performed using a Prominence Shimadszu system 
(Shimadzu Scientific Instruments) and a Superdex 200 5/150 GL column (GE 
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Healthcare), and data were collected and analyzed by LC Solution Software (Shimadzu 
Scientific Instruments). The mobile phase was composed by PBS with 10 % glycerol –
buffer in which the purified protein was stored. Absorbance of the eluant was 
monitored over the wavelength 220 nm. Retention times were calibrated with the 
following protein molecular mass standards: aprotinin (6.5 kDa) (AppliChem), 
Ribonuclease A (13.7 kDa), Carbonic anhydrase (29 kDa), Ovalbumin (43 kDa), 
Conalbumin (75 kDa), Aldolase (158 kDa), and Ferritin (440 kDa) (all from GE 
Healthcare). 
 
2.1.7. LC-MS OF INTACT DJ-1 
The purified DJ-1 was cleaned and desalted using Strong Cation Exchage (SCX) 
followed by C4 Bond Elut OMIX tips (Agilent technology). SCX tips were wetted with 
200 μL of 0.1% FA and equilibrated with 400 μL of 1% FA. Protein (185 μg in 0.1 % FA) 
was bind to the column (in 3 cycles of aspirate-dispense) and washed with 400 μL of a 
0.1 % FA solution in methanol. Finally, protein was eluted with 30% methanol in 0.1 M 
solution of NaOH. 
Then, sample was desalted using C4 tips. Sample was pre-treated with FA to 
adjust the solution to 5% FA. C4 tips were hydrated with 30 μL of 90% ACN and 5% of 
FA and equilibrated with 180 μL of 5% FA. Protein molecules were loaded to the 
columns (in 3 cycles of aspirte-dispense), followed by a washing step with 60 μL of 5% 
FA solution and elution to new tubes with 120 μL of 90 % ACN and 5% of FA. The 
eluted protein molecules were concentrated using the Concentrator Plus (Eppendorf) 
at 60 °C. Sample volume was adjusted to 30 μL in a solution of 2 % ACN and 0.1 % FA 
and transferred into vials for posterior LC-MS/MS analysis. 
Proteins were resolved by liquid chromatography (nanoLC Ultra 2D, Eksigent) 
on a ChromXP™ C18 reverse phase trap-column (350 μm ID × 0.5mm length, 3 μm 
particles, 120 Å pore size, Eksigent) at 7 μL/min. Proteins were eluted into the mass 
spectrometer with an acetonitrile gradient in 0.1% FA (2% to 98% ACN, in a multiple 
step gradient for 12 min), using an electrospray ionization source (DuoSpray™ Source, 
ABSciex). The mass spectrometer (Triple TOF™ 5600 System; ABSciex) was 
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programmed for scanning full spectra (600-1250 m/z, operated by Analyst® TF 1.5.1, 
ABSciex). 
Intact mass was determined using BioAnalyst™ Software (ABSciex). Briefly, the 
deconvolution of the spectra was obtained by Baesian Protein Reconstruct of the 
average of the maximum spectra possible, with the following parameters: mass range 
from 15 to 30 kDa (determined according with the expected protein molecular 
weight), spectrum limit range from 620 to 1000 m/z (determined according with 
protein charge envelope profile), signal to noise threshold of 10 (according with the 
ration from the less intense peak used in calculation to the noise determined by a 
script present in Analyst). From the deconvoluted sprectrum it was chosen a peak from 
the isotopic distribuition for modelling the data that was then used to calculate the 
molecular weight of the protein. 
 
2.2. SH-SY5Y CELL CULTURE 
Human neuroblastoma SH-SY5Y cells were cultured in Dulbecco's modified 
Eagle medium (DMEM) with Glutamax™ and low glucose (1 g/L) (Gibco), supplemented 
with fetal bovine serum (FBS) (Gibco) (10 %), amphotericin B solution (Invitrogen) (1.25 
μg/mL) and penicilin-streptomycin solution (Pen-Strep) (Cambrex) (1 %). In order to 
facilitate the reading this supplemented culture medium will be referred only as 
DMEM with the reference to the percentage of FBS contained. For cell passage, cells 
were washed with Dulbeccoʹs phosphate buffered saline (DPBS) (Cambrex, Charles 
City, IA) and detached with trypsin-EDTA (0.05 % solution in phosphate buffered saline 
(PBS)) (Invitrogen). 
Cells were maintained at 37 °C, 5 % CO2/95 % air in a humidified incubator (Shel 
Lab 3517-2) (Sheldon Manufacturing, Inc.). 
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2.3. CELL VIABILITY UNDER OXIDATIVE STRESS 
2.3.1. CELL CULTURE 
SH-SY5Y cells were seeded at 46.9×103 cells/cm2 in DMEM with 10 % FBS in 96-
well plates (Corning) at 37 °C, 5 % CO2/95 % air in a humidified incubator (Sheldon 
Manufacturing, Inc.). 
 
2.3.2. OXIDATIVE STRESS STIMULI 
Four hours after plating, cells were stimulated with different concentrations 
(25-10,000 μM) of H2O2 (Sigma-Aldrich) in DMEM with 0.1% of FBS for 24 h. The 
culture medium was totally exchanged to the referred above H2O2 solutions, freshly 
made. Control condition consisted in exchange the culture medium to DMEM with 
0.1% of FBS. 
 
2.3.3. CELL VIABILITY ASSESSMENT 
Cell viability was assessed by using the Cell Titer-Glo® Luminescent assay 
(Promega) in white opaque 96-well plates (Corning). The luminescent signal was 
detected by a LUMIstar Galaxy automated microplate luminescence reader (BMG 
Labtech), according to the manufacturer’s instructions. 
 
2.4. DJ-1-MEDIATED NEUROPROTECTION 
2.4.1. OXIDATIVE STRESS AND DJ-1 STIMULI 
Four hours after plating (as described on section 2.3.1) cells were stimulated 
with different concentrations (25, 50, 100 and 200 μM) of H2O2 (Sigma-Aldrich) in 
DMEM with 0.1 % of FBS in the presence or absence of recombinant His-tagged human 
DJ-1 protein (1 or 5 μM) or the corresponding vehicle (PBS with 10 % of glycerol) for 24 
h. Control condition consisted in exchange the culture medium to DMEM with 0.1% of 
FBS. 
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2.5. ACTIVATION OF AKT AND ERK1/2 SIGNALLING PATHWAYS 
2.5.1. CELL CULTURE AND DJ-1 STIMULI 
SH-SY5Y cells were seeded at 75×103 cells/well in DMEM with 10 % FBS in 12-
well plates (Corning) at 37 °C, 5 % CO2/95 % air in a humidified incubator (Sheldon 
Manufacturing, Inc.). Twenty-four hours after plating, cells were serum starved by 
changing the culture medium to DMEM with 0.1 % FBS. After 16 h of serum starvation, 
cells were treated with 1 μM of recombinant DJ-1 (or equivalente volume of vehicle – 
PBS with 10% glycerol) for 0, 15, 30 and 60 min. Starved cells were also treated with 
200 μM or 1 mM of H2O2, in the presence or absence of 1 μM of recombinant DJ-1 for 
15 min. The positive control condition for Akt and ERK1/2 activation was the addition 
of 15 % of FBS to the culture medium of starved cells. Stimulation was terminated by 
aspiration of the medium and performing the cellular protein extracts. 
 
2.5.2. CELLULAR PROTEIN EXTRACTS 
Cells were washed and then scraped with ice-cold PBS supplemented with 
Complete Mini protease inhibitor mixture and Complete Mini phosphatase inhibitor 
mixture (inhibitors cocktail) (Roche) using rubber cells scraper (TPP, Switzerland). Cells 
were collected to microcentrifuge tubes and centrifuged at 500×g for 5 min at 4 °C. 
Pellets were resuspended in ice-cold RIPA buffer (50 mM Tris-HCl, pH 7.4; 1% (v/v) 
Igepal; 0.25% (v/v) sodium-deoxycholate; 150 mM NaCl; 1 mM DTT; 1 mM EDTA and 
the inhibitors cocktail). After three freeze-thaw cycles, cell lysates were centrifuged at 
20,000×g for 15 min at 4 °C and the supernatant was collected to a new tube and 
stored at -20 °C, until further use. The protein concentration of each protein extract 
was determined by using the BCA protein determination assay (Thermo 
Fisher Scientific). 
 
2.5.3. IMMUNOBLOT DETECTION 
The cellular extracts (50 μg of total protein) were denatured with sample buffer 
(6×) [0.35 M Tris-HCl, pH 6.8 with 0.4 % SDS (v/v), 30 % glycerol (v/v), 10 % SDS (w/v), 
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9.3 % DTT (w/v) and 0.01 % bromophenol blue (w/v)] by boiling at 95°C for 5 min and 
then electrophoretically separated on a 10 % SDS-polyacrylamide gel (Bio-Rad) using a 
Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad). Proteins were transferred to 
Trans-Blot® Turbo™ polyvinylidene fluoride (PVDF) membranes (Bio-Rad) using a 
Trans-Blot® Turbo™ Transfer System (Bio-Rad). After transfer, the membranes were 
blocked for 1 hour at room temperature (RT) with 5% (w/v) skimmed milk powder 
dissolved in PBS with 0.1 % (v/v) Tween-20 (PBS-T) (Bio-Rad).  
Membranes were then incubated with primary antibodies against the total 
form of Akt  and ERK1/2: rabbit Anti-total ERK1/2 (1:500) [Cell Signaling Technology, 
Inc.(# 9272)], mouse Anti- total ERK1/2 (1:500) [Cell Signaling Technology, Inc.(#4695)]; 
or against the phosphorylated form of Akt  and ERK1/2: rabbit Anti-P-Akt (Ser473) 
(1:500) [Cell Signaling Technology, Inc.(#9271)] and rabbit Anti-P-ERK1/2 
(Thr202/Tyr204) (1:500) [Cell Signaling Technology, Inc.(#4377)] in 5% (w/v) skimmed 
milk powder dissolved in PBS-T – overnight at 4 °C followed by 1 hour at RT. Primary 
antibodies were removed and membranes were washed with PBS-T (3 times for 15 min 
and under agitation). Blots were then incubated for 2 hour at RT with the secondary 
antibodies conjugated with alkaline phosphatase [anti-rabbit (1:3,000) and anti-mouse 
(1:10,000), both from Jackson ImmunoResearch Laboratories, Inc.], in 5% (w/v) 
skimmed milk powder dissolved in PBS-T, followed by three washes as above. After the 
incubation of membranes with the phospho- and total-specific antibodies, they were 
stripped and re-probed with a mouse antibody against glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (sc-47724) (Santa Cruz Biotechnology, Inc.) used as protein 
loading control. 
To observe protein-immunoreactive bands, membranes were incubated with 
“Enhanced Chemifluorescence (ECF) detection system” (GE Healthcare) and visualized 
using a Molecular Imager FX System (Bio-Rad). The adjusted volumes (total intensities 
in a given area with local background subtraction) for each band were obtained using 
Quantity One® version 4.6 software (Bio-Rad). 
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2.6. DJ-1 INTERNALIZATION 
2.6.1. OXIDATIVE STRESS STIMULI 
SH-SY5Y cells were seeded in 148 cm2 plates (Corning) at 5×106 cells/plate in 
DMEM with 10 % FBS and maintained in culture for 48h at 37 °C, 5 % CO2/95 % air in a 
humidified incubator (Sheldon Manufacturing, Inc.). Cells were treated with 1 μM of 
recombinant DJ-1 in the presence or absence of H2O2 (Sigma-Aldrich) (200 μM) in 
DMEM with 0.1 % FBS and they were incubated for 4 h at 37 °C, 5 % CO2/95 % air in a 
humidified incubator. The control condition consisted in the same condition except the 
addition of DJ-1 and H2O2. 
 
2.6.2. CELLULAR FRACTIONATION AND PROTEIN EXTRACTS 
The culture medium (in the presence or absence of the recombinant DJ-1 or DJ-
1 and H2O2) was removed and cells were washed with PBS four times. Then, cells were 
treated with 1.5 mM of DTSSP (crosslinker) (Thermo Fisher Scientific) for 30 min at 37 
°C, 5 % CO2/95 % air in a humidified incubator (Sheldon Manufacturing, Inc.). The 
crosslinker was quenched by incubation with Tris-HCl (15 mM, pH 7.4) for 15 min at 37 
°C, 95 % air and 5 % CO2 in humidified incubator. 
After removing the crosslinker and Tris-HCl solution, cells were scraped and 
pulse-sonicated (1 sec pulses for 10 sec with 40 % amplitude) (Vibra-Cell™ VCX130) 
(Sonics & Materials) in Tris-HCl (50 mM, pH 7.4) with Complete Mini protease inhibitor 
mixture and Complete Mini phosphatase inhibitor mixture (inhibitors cocktail) (Roche). 
Cellular debris were removed by a centrifugation at 1,000×g for 5 min. The 
supernatant was centrifuged at 126,000×g for 1h at 4 °C to separate it into the 
cytosolic (supernatant) and membrane (pellet) fractions. The membrane fraction was 
washed with ice-cold PBS suplemmented with inhibitors cocktail and then centrifuged 
again at 126,000×g for 1h at 4 °C. The pellet was resuspended in RIPA buffer (50 mM 
Tris-HCl, pH 7.4; 1% (v/v) Igepal; 0.25% (v/v) sodium-deoxycholate; 150 mM NaCl; 1 
mM DTT; 1 mM EDTA and inhibitors cocktail) and both fractions were incubated with 
the His-trap resin (GE Healthcare) for 1h at 4 °C at 1400 rpm in the thermomixer 
(Eppendorf). 
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Samples were then centrifuged at 1,000×g for 3 minutes, the supernatant 
containing proteins that did not bind to His-trap resin was collected to a new tube and 
the resin was denaturated with sample buffer (2×), without DTT (to avoid the cleavage 
of DTSSP) at 95 °C, for 15 minutes with agitation. Proteins eluted from the resin were 
collected after a centrifugation at 1,000×g for 3 minutes. All fractions were stored at -
20 °C until further use. Fractions of proteins that did not bind to His-trap resin were 
concentrated using concentrators with a cut-off of 5 kDa (500 μL) (Sartorius). Protein 
content was determined in all samples using the RC-DC method (Bio-Rad), according to 
the manufacturer’s instructions. 
 
2.6.3. IMMUNOBLOT DETECTION 
Samples were denaturated with sample buffer (6×) with DTT at 95 °C for 5 min 
and then electrophoretically separated on 12.5 % SDS-polyacrylamide gel (equal 
amounts of protein per lane) using a Mini-PROTEAN Tetra Electrophoresis System (Bio-
Rad). Proteins were transferred to Trans-Blot® Turbo™ polyvinylidene fluoride (PVDF) 
membranes (Bio-Rad) using a Trans-Blot® Turbo™ Transfer Starter System (Bio-Rad). 
After transfer, the membranes were blocked for 1 hour at room temperature (RT) with 
5% (w/v) skimmed milk dissolved in PBS with 0.1 % (v/v) Tween-20 (PBS-T) (Bio-Rad). 
Membranes were then incubated with primary antibodies: goat Anti-DJ-1 C-16 (1:200) 
[Santa Cruz Biotechnology, Inc. (sc-27006)], in 5% (w/v) skimmed milk powder 
dissolved in PBS-T, overnight at 4°C followed by 1 hour at RT or mouse Anti-His Tag 
TM0243 (1:5,000) (GenScript), in 5% (w/v) skimmed milk powder dissolved in PBS-T, 
for 1 hour at RT. Primary antibodies were removed and membranes were washed with 
PBS-T (3 times for 15 min under agitation). Blots were then incubated for 1 hour at RT 
with the secondary antibodies conjugated with alkaline phosphatase (anti-goat 
(1:1,000) and anti-mouse (1:10,000) both from Jackson ImmunoResearch Laboratories, 
Inc., respectively), in 5% (w/v) skimmed milk powder dissolved in PBS-T, followed by 
three washes as above. To observe protein-immunoreactive bands, membranes were 
incubated with “Enhanced Chemifluorescence (ECF) detection system” (GE Healthcare) 
and visualized in a Molecular Imager FX System (Bio-Rad). 
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2.7. EXTRACELLULAR DJ-1 INTERACTOME 
2.7.1. CELL CULTURE AND PULL-DOWN ASSAY 
SH-SY5Y cells were seeded at 25×103 cells/cm2 in 148 cm2 plates (Corning) in 
DMEM with 10 % FBS and maintained in culture for 48h at 37 °C, 5 % CO2/95 % air in a 
humidified incubator (Sheldon Manufacturing, Inc.). Then, cells were washed four 
times with PBS and twice with DMEM without FBS, warmed at 37 °C. Then, cells were 
maintained in culture with DMEM without FBS for further 48h at 37 °C, 5 % CO2/95 % 
air in a humidified incubator. The conditioned medium and culture medium that was 
not in contact with cells (negative control) were concentrated using 5 kDa cut-off 
concentrators (20 mL) (Sartorius). Cells were scraped with ice-cold PBS with the 
inhibitors cocktail (Roche) using rubber cells scraper (TPP), and collected to 
microcentrifuge tubes and centrifuged at 500×g for 5 min at 4 °C. Pellets were 
resuspended in ice-cold RIPA buffer. After three freeze-thaw cycles, cell lysates were 
centrifuged at 20,000×g for 15 min at 4 °C and the supernatant was collected to a new 
tube and store at -20 °C, until further use. 
Concentrated culture mediums and total protein extracts (positive control) 
were then incubated with 100 μL of His-trap resin with or without recombinant DJ-1 
overnight at 4 °C at 1400 rpm in the thermomixer (Eppendorf). 
Following a centrifugation at 1,000×g for 3 minutes, the supernatant containing 
proteins that did not bind to His-trap resin was collected to a clean tube and the resin 
was denaturated with sample buffer (2×) at 95 °C, for 15 minutes with agitation. 
Proteins eluted from the resin were collected after a centrifugation at 1,000×g for 3 
minutes. All fractions were stored at -20 °C until further use. 
 
2.7.2. SDS-PAGE AND COOMASIE STAINING 
Samples were electrophoretically separated in a pre-cast 4-20 % SDS-
polyacrylamide gel (Bio-Rad) using a Mini-PROTEAN Tetra Electrophoresis System (Bio-
Rad) and stained with Coomasie Brilliant Blue G-250 (Bio-Rad). The gel band processing 
was done as described in section 2.1.4 and protein identification as described on 
section 2.1.5. Peptide identification was also performed using Protein Pilot software 
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(v4.5, ABSciex), as described on section 2.1.5., but searching using the SwissProt 
database, against Homo sapiens and all species. 
 
2.8. STATISTIC ANALYSIS 
Statistical analysis of results from cell viability was performed using SPSS 
(Statistical Package for the Social Sciences) version 17.0 (IBM®). Statistical significance 
was considered relevant for *p < 0.05, **p < 0.01 and ***p < 0.001 using Two-way 
ANOVA (Analysis Of Variance). The ANOVA analysis was followed by Tukey HSD post 
hoc test for comparison among experimental conditions. Parametric assumptions (data 
normality and homoscedasticity) were tested using Shapiro-Wilk Test and Levene’s 
Test, respectively. Data presented as mean ± standard error of the mean (S.E.M.) Every 
experimental condition was tested in four sets of independent experiments, unless 
specified.
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DJ-1 has been associated with familial early onset Parkinson’s disease [57, 107-
108] as DJ-1 dysfunction leads to neurodegeneration [56, 58, 109]. The exact 
mechanisms by which DJ-1 confers neuroprotection remain to be clarified, but this 
protein has been suggested to participate in oxidative stress response [52] and to act 
as a sensor for oxidative stress [55]. A DJ-1 astrocyte-mediated neuroprotection has 
been suggested [139] highlighting the potential of extracellular neuroprotective 
mechanisms of this protein. In order to mimic the presence of extracellular DJ-1 
secreted by astrocytes, the first task of this project consisted in the production of a 
recombinant DJ-1 protein to study the effect of an exogenous addition of this protein 
to neuronal cells, under normal or oxidative stress conditions. 
 
3.1. RECOMBINANT DJ-1 PRODUCTION AND CHARACTERIZATION 
Recombinant DJ-1 was expressed in E. coli BL21star (DE3) strain and purified by 
chromatography, using a His-Trap column (Figure 3.1), since the produced protein 
contains a His-tag. The amount of protein in fractions from DJ-1 expression and 
purification steps, including fractions corresponding to the higher intensity peaks 
(fractions 1, 2, 3 and 4 - Figure 3.1) were quantified using the 2-D Quant kit, 
electrophoretically separated and stained with Colloidal Coomassie Brilliant Blue G-250 
(Bio-Rad) and silver (only fraction 3 and fraction of purified DJ-1, after the dialysis) to 
observe the protein content profile (Figure 3.2). The most concentrated fraction - 
fraction 3 - (corresponding to the highest chromatographic peak and eluted at 300 mM 
Imidazole - Figure 3.1) was dialysed against PBS and stored at -80 °C in PBS with 10 % 
of glycerol at a final concentration of 1.85 μg/μL. 
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FIGURE 3.1| CHROMATOGRAM OF DJ-1 PURIFICATION BY AFFINITY CHROMATOGRAPHY. The 
chromatography was performed in an His-Trap column. Fractions represented by grey bars correspond 
to the collected fractions of each elution step. Fraction 1 - eluted fraction with 10 mM Imidazole; 
fraction 2 - eluted fraction with 50 mM Imidazole; fraction 3 - eluted fraction with 100 mM Imidazole; 
and fraction 4 eluted fraction with 300 mM Imidazole. 
 
 
FIGURE 3.2| SDS-PAGE OF DIFFERENT FRACTIONS OF RECOMBINANT DJ-1 PURIFICATION. A - SDS-
PAGE followed by coomassie staining. MW – molecular weight marker; BI – before expression 
induction; AI – after expression induction; Ld – loaded on the his-trap column; FT – flow-through of the 
his-trap column; 1 – eluted fraction 1; 2 – eluted fraction 2; 3 – eluted fraction 3; 4 – eluted fraction 4; 
DJ-1 – purified DJ-1 after dialysis of fraction 3. B - SDS-PAGE followed by silver staining. 3 – eluted 
fraction 3; DJ-1 – purified DJ-1 after dialysis of fraction 3. 
 
The results indicate that before the protein expression induced with IPTG (BI), 
there is not a highly intense band at ≈22 kDa (expected mass of a DJ-1 monomer) 
(Figure 3.2, A). On the other hand, after the induction of DJ-1 expression (AI), a higher 
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intensity band appears at this molecular weight, as in the fraction loaded on the His-
trap column (Ld) (Figure 3.2, A). Moreover, in the flow through (FT) of the His-trap 
column, the highly intense band disappeared, indicating that almost all the 
recombinant protein was captured by the column (Figure 3.2, A). All the analysed 
eluted fractions (1, 2, 3 and 4 – higher chromatogram peaks) presented this band 
(Figure 3.2, A). The fraction of stored protein (after the dialysis step) has a highly 
intense band at ≈22 kDa, as expected (Figure 3.2, A and B). However, fraction 3 and 
the final fraction of purified DJ-1 (after dialysis) presented other bands (Figure 3.2, B). 
In order to understand what was the content of these fractions besides DJ-1, bands 
were digested and analysed by LC-MS/MS. 
 
3.1.1. PROTEIN IDENTIFICATION BY LC-MS/MS 
The produced recombinant protein has some protein contaminants in both 
analysed fractions: fraction 3 and the final fraction of purified DJ-1 (after dialysis of 
fraction 3) (Figure 3.1 and Figure 3.2). The analysis of gel bands digests by LC-MS/MS 
(Table 3.1) shows that most of the protein contaminants are bovine proteins, probably 
contained in the LB medium used in bacterial culture, and Escherichia coli proteins, 
which was the host for the cloning and expression of the desired protein. 
Nevertheless, a high number of DJ-1 peptides were identified with a sequence 
coverage of 97.88 % (Table 3.1). The sequence coverage of recombinant DJ-1 relatively 
to the human protein is not 100% because the N-terminal of the recombinant DJ-1 was 
engineered to contain an hexahistidine tag and a TEV cleavage sequence, hence the 
differences to the human protein (Figure 3.3 - Protein Alignment using the ClustalW2 
tool). Although some alterations in protein folding and/or function may happen when 
a tag is added, in the case of DJ-1 the insertion of a tag in the C-terminal could be more 
prejudicial than in the N-terminal, because the putative DJ-1 active site is occluded by 
the C-terminal helix-kink-helix motif [164]. Moreover, the most deleterious DJ-1 point 
mutation, L166P, occurs in this C-terminal motif [164]. In addition, as DJ-1 is a 
relatively small protein, the used tag (an hexahistidine tag) is also a small one to 
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minimize the possible negative effects of its addition in terms of protein structure and 
function. 
 
TABLE 3.1| PROTEINS IN PURIFIED FRACTIONS OF THE RECOMBINANT PROTEIN. 
Protein ID  F 3 DJ-1 
Name Accessions Specie Unique 
Peptides 
Cov 
(95%) 
Unique 
Peptides 
Cov 
(95%) 
Protein DJ-1  Q99497|PARK7_HUMAN Homo sapiens   104 97.88 118 97.88 
Kappa-casein  P02668|CASK_BOVIN Bos taurus   14 45.79 18 46.32 
Alpha-S1-casein  P02662|CASA1_BOVIN Bos taurus   15 61.21 12 57.01 
Beta-casein  P02666|CASB_BOVIN Bos taurus   14 68.75 13 60.27 
Beta-lactoglobulin  P02754|LACB_BOVIN Bos taurus       15 59.55 
Alpha-S2-casein  P02663|CASA2_BOVIN Bos taurus   10 33.78 7 27.93 
Serum albumin  P02769|ALBU_BOVIN Bos taurus   8 10.54 6 8.57 
Glycosylation-
dependent cell adhesion 
molecule 1  
P80195|GLCM1_BOVIN Bos taurus   3 22.88 3 27.45 
Lactadherin  Q95114|MFGM_BOVIN Bos taurus       2 3.28 
Alpha-lactalbumin  P00711|LALBA_BOVIN Bubalus bubalis   1 7.04 2 7.04 
50S ribosomal protein L2  P60422|RL2_ECOLI Escherichia coli   23 62.27 11 38.83 
50S ribosomal protein 
L28  
P0A7M2|RL28_ECOLI Escherichia coli   5 33.33 1 12.82 
50S ribosomal protein 
L17  
P0AG44|RL17_ECOLI Escherichia coli   4 20.47     
Ferric uptake regulation 
protein  
P0A9A9|FUR_ECOLI Escherichia coli   3 27.03 3 30.41 
FKBP-type peptidyl-
prolyl cis-trans 
isomerase slyD  
P0A9K9|SLYD_ECOLI Escherichia coli      2 10.2 
Beta-galactosidase  P00722|BGAL_ECOLI Escherichia coli   1 1.94     
Uncharacterized protein 
yqjI  
P64588|YQJI_ECOLI Escherichia coli   1 4.35     
50S ribosomal protein 
L21  
P0AG48|RL21_ECOLI Escherichia coli   1 11.65     
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FIGURE 3.3| SEQUENCE ALIGNMENT OF THE PRODUCED RECOMBINANT DJ-1 AND THE HUMAN 
PROTEIN. “*” means that the residues in that position are identical in both sequences. Red - small and 
hydrophobic residues; blue - acidic residues; magenta - basic residues; green - residues with hydroxyl, 
amine or basic groups in its lateral chain. 
 
The recombinant DJ-1 sequence was found with 100 % of coverage in the case 
of DJ-1 fraction (fraction of the purified protein after dialysis of fraction 3) and with 
99.6% in the case of fraction 3 (Figure 3.4). This fact must be due to the lack of the 
initial methionine in the final sequence, probably removed by E. coli methionyl-
aminopeptidase [165]. Actually the initial methionine could be identified in DJ-1 
sequence of DJ-1 fraction, which can be due to the overexpressing system used that 
can overload the capacity of removing the initial methionine. 
 
 
FIGURE 3.4| COVERAGE OF THE RECOMBINANT DJ-1 SEQUENCE IN FRACTION 3 AND DJ-1 FRACTION. 
Green - residues identified in peptides with at least 95% confidence; grey - unidentified residues. 
44 | RESULTS 
 
3.1.2. MOLECULAR SIZE EXCLUSION CHROMATOGRAPHY 
DJ-1 exists as homodimer [112] and this seems to be the functionally relevant 
form of the protein [128-129]. In order to assess the form of the purified protein, an 
HPLC-size exclusion chromatography was performed. Standards retention time were 
used to perform a calibration curve (Figure 3.5 and Supplementary Figure 7.1) and the 
molecular weight of purified DJ-1 was determined using the retention time of DJ-1 
sample (Figure 3.5). The molecular weight of the purified DJ-1 is ≈43 kDa, which 
corresponds to the dimer form [105]. 
 
 
FIGURE 3.5| HPLC-SIZE EXCLUSION PURIFIED DJ-1 CHROMATOGRAM AND STANDARDS CALIBRATION. 
Standards from left to right: Ferritin (440 kDa); Aldolase (158 kDa); Conalbumin (75 kDa); Ovalbumin 
(43 kDa); Carbonic Anhydrase (29 kDa); Ribonuclease A (13.7 kDa); Aprotinin (6.5 kDa). 
 
To confirm the molecular weight of the monomeric form of DJ-1 protein, the 
purified protein was analysed by LC-MS. 
 
3.1.3. LC-MS OF INTACT DJ-1 
The theoretical molecular weight (average) of recombinant DJ-1 produced, 
without the initial methionin, calculated using the Mass Calculator tool (Bioinformatics 
Solutions, Inc.), was 22739.998 Da. The molecular weight predicted using the mass 
spectrum of protein charge envelop of intact DJ-1 (Figure 3.6) and the 
BioAnalyst™ Software was 22739.1091 Da, which is a very proximal value (a shift of 
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0.8889 Da). Thus, the produced recombinant DJ-1 has the predicted molecular mass of 
the protein and is present, in solution, as a dimer (Figure 3.6 and Figure 3.5). 
 
 
FIGURE 3.6| ESI-MS ANALYSIS OF INTACT DJ-1. A – Blue - Mass spectrum of protein charge envelop of 
intact DJ-1. Red – Deconvoluted mass spectrum of protein charge envelop of intact DJ-1. B – Graphic of 
deconvoluted masses using BioAnalyst™. 
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In order to address if the recombinant DJ-1 is functional, its neuroprotective 
capacity against oxidative stress was tested. 
 
3.2. CELL VIABILITY UNDER OXIDATIVE STRESS 
The human neuroblastoma SH-SY5Y cell line has been widely used as an in vitro 
model of dopaminergic neurons for Parkinson’s disease [166] and, is known to be 
responsive to oxidative stress caused by hydrogen peroxide [139, 167-169]. SH-SY5Y 
cells were sensitive to the oxidative stress-inducer hydrogen peroxide in a dose 
dependent manner (Figure 3.7), as expected, with a LD50 value of 247.4 μM. This 
dose-response curve (Figure 3.7) allowed the choice of hydrogen peroxide 
concentrations used in further assays. 
 
 
FIGURE 3.7| H2O2-INDUCED CELL DEATH. SH-SY5Y cells were treated with various concentrations of 
hydrogen peroxide, 4 h after plating. After 24 h, cell viability was assessed using the Cell Titer-Glo® 
assay. Data are the mean±SEM of four determinations. 100% viability was based on untreated cultures. 
 
3.3. DJ-1-MEDIATED NEUROPROTECTION 
Reports have shown the inhibition of H2O2-induced cell death by the exogenous 
addition of recombinant DJ-1 protein [139, 170]. To address this, cells were treated 
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with different concentrations of H2O2 in the presence of 1 μM DJ-1 (or 5 μM – 
Supplementary Figure 7.3) (or the corresponding volume of vehicle). The results 
indicate a significant inhibition of cell death as a result of DJ-1 action (Figure 3.8), 
indicating that DJ-1 is in its functional form. 
 
 
FIGURE 3.8| PROTECTIVE EFFECT OF RECOMBINANT DJ-1 AGAINST H2O2-INDUCED OXIDATIVE STRESS. 
SH-SY5Y cells were treated with H2O2 (25, 50, 100 and 200 μM) in the presence or absence of 
recombinant His-tagged human DJ-1 protein (1 μM) or vehicle, 4h after plating. After 24 h, cell viability 
was assessed by the Cell Titer-Glo assay. Data are the mean±SEM of four determinations, based on 
untreated cultures as 100% of viability. Significance (Tukey HSD post hoc comparisons after Two-way 
ANOVA): ***p < 0.001 treatment with H2O2 and vehicle vs. treatment with vehicle alone. #p < 0.05, ##p 
< 0.01 treatment with H2O2 and DJ-1 vs. corresponding treatment with H2O2 and vehicle.  
 
The treatment of SH-SY5Y cells with 50, 100 and 200 μM H2O2 induced cell 
death (Figure 3.8 black bars) in presence of the protein’s vehicle. In contrast, the 
presence of 1 μM His-tagged recombinant human DJ-1 protein significantly increased 
cell viability in all the corresponding conditions (Figure 3.8 white bars). 
 
The neuroprotective effect of DJ-1 against H2O2-induced cell death has been 
associated with the activation of pro-survival [103, 117-120] and inhibition of pro-
apoptotic pathways [121-123], such as Akt and ERK1/2 signalling pathways. Thus, 
another task of this project was to observe if these signalling pathways were activated 
by DJ-1 under normal or oxidative stress conditions. 
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3.4. ACTIVATION OF AKT AND ERK1/2 SIGNALLING PATHWAYS 
There are reports suggesting that DJ-1 activates Akt [103, 120] and ERK1/2 
[117] signalling pathways. All of them showed a DJ-1 mediated activation of these 
signalling pathways, using strategies of DJ-1 over-expression, inhibition of its 
expression or function, inside the cells. In order to assess if the purified DJ-1 can also 
activate these signalling pathways in SH-SY5Y cells when it is exogenously added 
(which has never been reported), under normal or oxidative stress conditions, 
immunoblot experiments using phospho-specific antibodies were performed. 
SH-SY5Y cells were first serum starved to reduce the basal level of activation of 
Akt and ERK1/2 signalling pathways, induced by several soluble factors present in the 
serum. Then, cells were treated with 1 μM of recombinant DJ-1 (or the vehicle) for 0, 
15, 30 and 60 min (Figure 3.9 and Figure 3.10), and with 200 μM or 1 mM of H2O2, in 
the presence or absence of recombinant DJ-1 for 15 min (Figure 3.11 and Figure 3.12). 
The time-points of the experiment were determined based on a previous work (Sandra 
Anjo’s master project – unpublished data) (Supplementary Figure 7.12). 
Although these are preliminary results, they show an apparent increase in 
phosphorylation of Akt (Figure 3.9), ERK1 and ERK2 (Figure 3.10) upon incubation of 
SH-SY5Y cells with recombinant DJ-1 (this increase was not observed when cells were 
treated with the vehicle alone). In the case of immonoblot detection of Akt 
phosphorylation, an increase of phosphorylation by exogenous DJ-1 was observed in 
all time-points, with maximum activation after 60 minutes of treatment (Figure 3.9). 
Phosphorylation levels of ERK1 and ERK2 were also increased by the exogenous 
addition of DJ-1 in all time-points, with maximum activation at 60 min of treatment in 
the case of ERK1, and at 30 min in the case of ERK2 (with a slight decrease at 60 min) 
(Figure 3.10). 
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FIGURE 3.9| TIME-COURSE PROFILE FOR DJ-1-INDUCED AKT ACTIVATION IN SH-SY5Y CELLS. Serum-
starved SH-SY5Y cells were treated with 1 μM of 6-His-DJ-1 (or vehicle) for the indicated periods of time 
and equal amounts of protein extract were analysed for Akt (60 kDa) activation by Western blot using 
phospho-specific Akt (Ser473) antibody or anti-total Akt, and anti-GAPDH antibodies to check protein 
loading. A - representative Western blot for the treatment with the recombinant protein; B - 
representative Western blot for the treatment with the vehicle;  C - graphic representation of the 
measured adjusted volume of each band. Data was normalized to the positive control (C+ - 15% FBS 
stimulation) for each western-blot. 
 
FIGURE 3.10| TIME-COURSE PROFILE FOR DJ-1-INDUCED ERK1/2 ACTIVATION IN SH-SY5Y CELLS. 
Serum-starved SH-SY5Y cells were treated with 1 μM of 6-His-DJ-1 (or the vehicle) for the indicated 
periods of time and equal amounts of protein extract were analysed for ERK1 (44 kDa) and ERK2 (42 
kDa) activation by Western blot using phospho-specific ERK1/2 (Thr202/Tyr204) antibody or anti-total 
ERK1/2, and anti-GAPDH antibodies to check protein loading. A - representative Western blot for the 
treatment with the recombinant protein; B - representative Western blot for the treatment with the 
vehicle;  C - graphic representation of the measured adjusted volume of each ERK1 corresponding band; 
D - graphic representation of the measured adjusted volume of each ERK2 corresponding band. Data 
was normalized to the positive control (C+ - 15% FBS stimulation) for each western-blot. 
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Although an activation of these pathways was already observed when SH-SY5Y 
cells were treated with H2O2 (1 mM) for different time periods [171], the activation of 
these pathways by a simultaneous incubation with exogenous DJ-1 and H2O2 was 
never tested. An increase of Akt (Figure 3.11) and both ERK1 and ERK2 (Figure 3.12) 
phosphorylation was observed after 15 min of treatment with 200 μM of H2O2, in the 
presence or absence of recombinant DJ-1 (1 μM). The Akt activation after 15 min of 
treatment had been shown in DJ-1+/+ cortical neurons treated with 100 μM of H2O2, 
and not observed in DJ-1-/- cortical neurons in the same conditions [120]. Moreover, 
using 1 mM of H2O2 the activation of both pathways was not observed, in the presence 
or absence of the recombinant protein (Figure 3.11 and Figure 3.12). Nevertheless, an 
activation of Akt and ERK1/2 activation in SH-SY5Y cells treated with 1 mM of H2O2 was 
already observed after 5, 10 and 20 minutes [171], so these results must be validated. 
 
 
FIGURE 3.11| H2O2-INDUCED AKT ACTIVATION, IN THE PRESENCE OR ABSENCE OF THE 
RECOMBINANT DJ-1, IN SH-SY5Y CELLS. Serum-starved SH-SY5Y cells were treated with 200 μM or 1 
mM of H2O2, in the presence or absence of 1 μM of 6-His-DJ-1, during 15 minutes. Equal amounts of 
protein extract were analysed for Akt (60 kDa) activation by Western blot using phospho-specific Akt 
(Ser473) antibody or anti-total Akt, and anti-GAPDH antibodies to check protein loading. A - 
representative Western blot for the treatment with 200 μM or 1 mM of H2O2, in the presence or 
absence of 1 μM of 6-His-DJ-1; B - graphic representation of the measured adjusted volume of each 
band. Data was normalized to the positive control (C+ - 15% FBS stimulation) for each western-blot. 
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FIGURE 3.12| H2O2-INDUCED ERK1/2 ACTIVATION, IN THE PRESENCE OR ABSENCE OF THE 
RECOMBINANT DJ-1, IN SH-SY5Y CELLS. Serum-starved SH-SY5Y cells were treated with 200 μM or 1 
mM of H2O2, in the presence or absence of 1 μM of 6-His-DJ-1, during 15 minutes. Equal amounts of 
protein extract were analysed for ERK1 (44 kDa) and ERK2 (42 kDa) activation by Western blot using 
phospho-specific ERK1/2 (Thr202/Tyr204) antibody or anti-total ERK1/2, and anti-GAPDH antibodies to 
check protein loading.  A - representative Western blot for the treatment with 200 μM or 1 mM of H2O2, 
in the presence or absence of 1 μM of 6-His-DJ-1; B - graphic representation of the measured adjusted 
volume of each ERK1 corresponding band; C - graphic representation of the measured adjusted volume 
of each ERK2 corresponding band. Data was normalized to the positive control (C+ - 15% FBS 
stimulation) for each western-blot. 
 
Another question that remains to be answered is if recombinant DJ-1 is 
exerting its neuroprotective effect in the extracellular space or if it has to be 
internalized by cells to accomplish this effect. 
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3.5. DJ-1 INTERNALIZATION 
The secretion of DJ-1 from astrocytes is enhanced under oxidative stress 
conditions, with a potential role in astrocyte-mediated neuroprotection [139]. 
Moreover, the DJ-1 uptake by SH-SY5Y cells was already observed using a GST-tagged 
recombinant protein [143]. An hypothesis that remains to be clarified is whether 
secretion of DJ-1 from astrocytes may further be uptaken to play its neuroprotective 
role in target neurons. 
To answer this question, a first task was performed to attempt to detect the DJ-
1 internalization in SH-SY5Y cells, as described in section 2.6. A protein enrichment 
step was performed for cytosolic and membrane proteins by performing an 
ultracentrifugation at 126,000×g. This enrichment step allows to distinguish roughly if 
DJ-1 was internalized to the intracellular space, by observing if it is present in the 
cytosolic-enriched fraction, or if it interacts with any extracellular membrane protein, if 
it is present in the membrane-enriched fraction. In order to observe the efficiency of 
the experimental procedure, the sediment of the ultracentrifugation was confirmed to 
be enriched in membrane proteins (Figure 7.8) while the supernatant was enriched in 
cytosolic proteins (Figure 7.7), by immunoblott detection using specific antibodies 
against a cytosolic (GAPDH) and a membrane protein (transferrin receptor). 
Both fractions were used in a pull-down assay against the 6-His tag, using an 
His-trap resin and analyzed by western-blot, using specific antibodies against DJ-1 and 
against the His-tag (Figure 3.13). The use of both antibodies allows to have a more 
refined and accurate result, as if the recombinant DJ-1 is internalized or if it interacts 
with any membrane protein, it should be present in the cytosolic-enriched fraction or 
in the membrane-enriched fraction, respectively, in the immunobloting using each 
antibody. 
In the end of the pull-down using the His-trap resin, three different groups of 
samples were obtained: 
1. Fraction with all of the proteins that did not bind to the His-trap resins, in 
which it is expected to be the endogenous DJ-1, but not the recombinant 
DJ-1 that was exogenously added; 
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2. Fraction with proteins eluted from the His-trap resin – proteins that bound 
to the resin during the incubation period; 
3. Fraction of proteins that remained bound to the resin – if the elution step 
was not efficient. 
 
In the case of proteins that did not bind to the His-trap resin, in both protein-
enriched fractions, using the primary antibody anti-His (Figure 3.13, left panel), only 
the positive control (an SH-SY5Y total protein extract with the addition of 0.6 μg of the 
recombinant protein) presents a band corresponding to the recombinant DJ-1 protein 
(≈22 kDa). This means that there was no recombinant DJ-1 in the fraction of proteins 
that did not bind to the resin, as expected. So, if the recombinant DJ-1 is present - if it 
was uptake by SH-SY5Y cells and is present in the cytosolic-enriched fraction, or if it 
interacts with any membrane protein and is present in the membrane-enriched 
fraction - it must remain bound to the His-trap resin. 
In the cytosolic fraction (Figure 3.13 upper panel), in the case of the result with 
the primary antibody anti-DJ-1, all fractions present a band corresponding to DJ-1, 
because the endogenous protein does not bind to the His-trap resin. Thus, the 
endogenous DJ-1 is present in the first supernatant which contains proteins that did 
not bind to resin. In addition, the positive and the negative controls also presents a 
band corresponding to DJ-1 as they are SH-SY5Y total proteins extracts, so they contain 
the endogenous DJ-1, and the positive control contain even the recombinant protein 
added. 
In the case of the membrane fraction (Figure 3.13 bottom panel), with the 
primary antibody anti-DJ-1, only the positive and negative controls present a band 
corresponding to the endogenous DJ-1, as these are SH-SY5Y total protein extract (the 
positive control has also the addition of 0.6 μg of the recombinant DJ-1 to the extract). 
There are some unspecific bands between 75 and 30 kDa already observed with these 
antibodies.  
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FIGURE 3.13| IMMUNOBLOT RESULTS FROM CYTOSOLIC AND MEMBRANE PROTEIN FRACTIONS THAT 
DID NOT BIND TO THE HIS-TRAP RESIN. SH-SY5Y cells were treated with 1 μM or with 200 μM H2O2 and 
1 μM DJ-1 of DJ-1, for 4h. The control condition was cells maintained in culture only with DMEM. 
Cellular extracts were performed by scraping cells and cell fractionation was performed by ultra-
centrifugation. Cytosolic and membrane enriched fractions were incubated with the His-trap resin and 
western-blots were performed using an anti-DJ-1 and an anti-His antibody. The negative control is an 
SH-SY5Y total protein extract and the positive control is the same extract with the addition of 0.6 μg of 
the recombinant DJ-1. 
 
The upper results can indicate that the recombinant DJ-1 must be still bound to 
the resin, if it was internalized by SH-SY5Y cells or if it interacted with any membrane 
protein. Although, there is no evidence for a DJ-1 uptake by SH-SY5Y cells upon its 
exogenous addition, under normal or oxidative stress conditions, or even to its 
interaction with membrane proteins, as there are any reactive band corresponding to 
the recombinant protein is present in both cytosolic and membrane proteins eluted 
from the resin (supernatant after resin denaturation – proteins that bound to the His-
trap resin) (Figure 3.14).  
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FIGURE 3.14| IMMUNOBLOT RESULTS FROM CYTOSOLIC AND MEMBRANE PROTEIN ELUTED FROM 
THE HIS-TRAP RESIN. SH-SY5Y cells were treated with 1 μM or with 200 μM H2O2 and 1 μM DJ-1 of DJ-1, 
for 4h. The control condition was cells maintained in culture only with DMEM. Cellular extracts were 
performed by scraping cells and cell fractionation was performed by ultra-centrifugation. Cytosolic and 
membrane enriched fractions were incubated with the His-trap resin and western-blots were 
performed using an anti-DJ-1 and an anti-His antibody. The negative control is an SH-SY5Y total protein 
extract and the positive control is the same extract with the addition of 0.6 μg of the recombinant DJ-1. 
 
Only positive controls present a reactive band corresponding to the 
recombinant DJ-1 protein (≈22 kDa) (Figure 3.14). As previously indicated, there are 
some unspecific bands between 75 and 30 kDa already observed with this antibodies. 
 
In order to confirm that the recombinant protein didn’t remain bound to the 
resin, resins were also analysed by SDS-PAGE followed by western-blot (Figure 3.15), 
using the same specific antibodies used to analyse the other fractions of the pull-down 
against the His-trap resin. If the recombinant protein remained bound to the His-trap 
resin, it means that the elution step was not efficient. 
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FIGURE 3.15| IMMUNOBLOT RESULTS FROM CYTOSOLIC AND MEMBRANE PROTEIN STILL BOUNDED 
TO THE HIS-TRAP RESIN. SH-SY5Y cells were treated with 1 μM or with 200 μM H2O2 and 1 μM DJ-1 of 
DJ-1, for 4h. The control condition was cells maintained in culture only with DMEM. Cellular extracts 
were performed by scraping cells and cell fractionation was performed by ultra-centrifugation. 
Cytosolic and membrane enriched fractions were incubated with the His-trap resin and western-blots 
were performed using an anti-DJ-1 and an anti-His antibody. The negative control is an SH-SY5Y total 
protein extract and the positive control is the same extract with the addition of 0.6 μg of the 
recombinant DJ-1. 
 
Although, there is no recombinant DJ-1 bound to the resin (Figure 3.15), which 
means that the absence of a reactive band corresponding to DJ-1 in all samples was 
not due to a problem in the elution step. Only the positive control presents a band 
corresponding to the recombinant DJ-1, as it corresponds to a SH-SY5Y total protein 
extract with the addition of 0.6 μg of the recombinant DJ-1 directly to the whole cell 
extract. In summary, there is no evidence for DJ-1 uptake by SH-SY5Y cells and neither 
any evidence for DJ-1 interaction with any membrane protein. 
Other attempts were performed to try to observe the internalization of the 
recombinant DJ-1 in SH-SY5Y cells, as reported using a GST-DJ-1 [143], but none shown 
the uptake of this protein (Figure 7.4, Figure 7.5 and Figure 7.6). 
 RESULTS | 57 
 
Altogether, these results do not show any evidence for recombinant His-DJ-1 
uptake by SH-SY5Y cells, in contrast to what was reported by others using GST-DJ-1 
[143] and neither an interaction of DJ-1 with any membrane protein, as hypothesized. 
 
3.6. EXTRACELLULAR INTERACTOME OF DJ-1 
Without having any evidence for a DJ-1 internalization or even any interaction 
with membrane proteins, strategies to find DJ-1 extracellular interactors that could be 
related with DJ-1 neuroprotective effect observed (Figure 3.8) and previously reported 
[139, 170], were carried out. 
The conditioned medium of SH-SY5Y cells was used to perform a pull-down 
assay against recombinant DJ-1 previously bound to a His-trap resin. One of the control 
conditions consisted in a similar pull-down assay against the His-trap resin, without 
any DJ-1 bound. This control condition allowed discarding proteins that bound only to 
the resin and not to the protein. Other control conditions were similar pull-down 
assays performed with the culture medium (DMEM), without being in contact with 
cultured cells, against the His-trap resin with or without DJ-1 bound. This control 
condition allowed discarding identified proteins possibly present in the culture 
medium. 
This type of approach can identify some indirect interactors because the 
identified proteins can be interacting with other DJ-1 interactors and not directly with 
DJ-1. Moreover, in the future, other control condition that must be included is a pull-
down assay performed against the His-tag bound to the resin, as some identified 
proteins could be also interacting only with this region of the recombinant protein, 
which is not present in the human protein. 
The coomassie staining showed some differences in protein bands between the 
sample of the pull-down of proteins contained in the conditioned medium against the 
His-trap resin with DJ-1 bound to it and control conditions (Figure 3.16), which can be 
an indication for a DJ-1 interaction with different proteins. 
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FIGURE 3.16| EXTRACELLULAR INTERACTORS. SDS-PAGE stained with coomassie of samples of the 
extracellular interactors experiment. In the first lane there is the sample corresponding to the 
conditioned medium incubated with resin with DJ-1. Negative controls: conditioned medium incubated 
with resin without DJ-1; DMEM (culture medium that was not in contact with cultured cells) incubated 
with resin with DJ-1; DMEM incubated with resin without DJ-1. The positive control is the sample of the 
total protein extract incubated with resin with DJ-1. 
 
The analysis of the gel lanes by LC-MS/MS reveals the identity of proteins that 
putatively interact with exogenous recombinant DJ-1 in the extracellular space of cells 
(Table 3.2). Proteins present in control conditions were not considered as possible DJ-1 
interactors. The identified proteins were separated in secreted and non-secreted 
(Supplementary Table 7.2 and Table 7.3), and its relevant biological processes for this 
study were assessed, based on the Gene Ontology (GO) Annotation available on the 
Uniprot database. Among the identified proteins there are cell adhesion proteins, 
proteins involved in cellular processes, such as, axon guidance, cell migration and 
proliferation, carbohydrate metabolism, synaptic process and positive or negative 
regulation of signalling pathways (Table 3.2). 
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TABLE 3.2| PROTEINS FROM THE CONDITIONED MEDIUM PULL-DOWN WITH DJ-1. 
Name Accessions Relevant Biological Process Unique 
Peptides 
Probable 
carboxypeptidase X1  
Q96SM3|CPXM1_HUMAN cell adhesion 6 
proteolysis 
Annexin A2  P07355|ANXA2_HUMAN positive regulation of vesicle fusion 6 
Neurocan core 
protein  
O14594|NCAN_HUMAN axon guidance 6 
carbohydrate metabolic process 
cell adhesion 
chondroitin sulfate catabolic process 
regulation of synapse structural plasticity 
small molecule metabolic process 
Carboxypeptidase E  P16870|CBPE_HUMAN cellular protein modification process 6 
neuropeptide signaling pathway 
protein localization to membrane 
proteolysis 
Semaphorin-3C  Q99985|SEM3C_HUMAN axon guidance 6 
immune response 
neural crest cell migration 
neural tube development 
response to drug 
Inter-alpha-trypsin 
inhibitor heavy chain 
H2  
P19823|ITIH2_HUMAN hyaluronan metabolic process 5 
Complement 
component C7  
P10643|CO7_HUMAN complement activation, alternative pathway 3 
complement activation, classical pathway 
cytolysis 
innate immune response 
Insulin-like growth 
factor-binding 
protein 2  
P18065|IBP2_HUMAN aging 3 
cellular response to hormone stimulus 
regulation of cell growth 
response to drug 
response to glucocorticoid stimulus 
response to lithium ion 
response to mechanical stimulus 
response to retinoic acid 
response to stress 
signal transduction 
Vitronectin  P04004|VTNC_HUMAN cell adhesion mediated by integrin 2 
immune response 
negative regulation of endopeptidase activity 
positive regulation of peptidyl-tyrosine 
phosphorylat ion 
positive regulation of protein binding 
positive regulation of receptor-mediated 
endocytosis 
positive regulation of smooth muscle cell 
migration 
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positive regulation of vascular endothelial 
growth factor receptor signaling pathway 
positive regulation of wound healing 
smooth muscle cell-matrix adhesion 
Fibronectin  P02751|FINC_HUMAN acute-phase response 2 
peptide cross-linking 
regulation of cell shape 
substrate adhesion-dependent cell spreading 
Nidogen-1  P14543|NID1_HUMAN cell-matrix adhesion 2 
glomerular basement membrane development 
positive regulation of cell-substrate adhesion 
Integral membrane 
protein 2B  
Q9Y287|ITM2B_HUMAN apoptotic process 1 
induction of apoptosis 
nervous system development 
Glia-derived nexin  P07093|GDN_HUMAN long-term synaptic potentiation 1 
negative regulation of cell growth 
negative regulation of cell proliferation 
negative regulation of phosphatidylinositol 3-
kinase cascade 
positive regulation of astrocyte differentiation 
positive regulation of neuron projection 
development 
regulation of synaptic transmission, 
glutamatergic 
secretory granule organization 
Testican-1  Q08629|TICN1_HUMAN cell adhesion 1 
central nervous system neuron differentiation 
neuron migration 
signal transduction 
 
In addition, some proteins were found both in the pull-down assay performed 
using the recombinant protein bound to the His-trap resin, and using the His-trap resin 
without the addition of the recombinant protein. As one of these identified proteins 
was the endogenous DJ-1 protein, maybe some of these identified proteins can be 
interacting not only with the His-trap resin, but also with the endogenous DJ-1. So, 
some of these proteins could also be DJ-1 interactors in the extracellular space. Thus, 
proteins identified in both fractions are presented in the Supplementary Data (Table 
7.1). The experimental design of this experience must be improved to avoid the 
presence of the endogenous DJ-1 in this control condition. One of the possible 
improvements that can be done is the increase of the number of washing steps. 
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4| DISCUSSION 
Parkinson’s disease is a progressive neurodegenerative disorder which etiology 
and pathology are not completely understood [2, 61]. DJ-1, a multifunctional protein 
[105-106] in which mutations have been associated with familial Parkinson’s disease 
[56, 58, 108], has been highly studied over the last years. DJ-1 protein has been 
suggested to participate in response to oxidative stress [52] and to act as a sensor of 
oxidative stress [55]. This protein is expressed in neurons and in all glial cell types [106, 
124] and its expression and release from astrocytes was suggested to contribute to 
astrocyte-mediated neuroprotection [139]. Taking these facts together, this study 
intended to give some insights about the neuroprotective mechanisms of exogenous 
DJ-1, mimicking its release from astrocytes, in SH-SY5Y cells, a cell line widely used as 
an in vitro model of dopaminergic neurons for Parkinson’s disease studies [166]. 
Recombinant DJ-1 was produced in order to be used in further studies of DJ-1-
mediated neuroprotection against H2O2-induced cell death, DJ-1-mediated activation 
of signalling pathways, DJ-1 internalization and DJ-1 extracellular interactome. The 
sequence of DJ-1 coding DNA in the pSKB-3 vector was confirmed by Sanger DNA 
Sequencing, and the purified protein was ≈43 kDa (Figure 3.5), corresponding to its 
dimer form [105], which is an important functional feature of the protein [112, 128-
129]. There are some contaminant proteins in the final DJ-1 purification fraction, but 
these are mainly proteins from the LB medium, used for bacterial cultures and proteins 
from the host (E. coli) used to clone and express the protein of interest (Table 3.1). On 
the other hand, the amino-acid sequence of the purified protein only lacks the initial 
methionine (Figure 3.4), due to a natural post-translational process, having the 
predicted molecular weight of its monomers (Figure 3.6). 
When SH-SY5Y cells were treated with H2O2, the cell viability decreased in a 
dose-dependent manner (Figure 3.7), but when cells were treated simultaneously with 
DJ-1, the H2O2-induced cell death was significantly inhibited in almost all conditions 
(Figure 3.8 white bars). This protective effect of DJ-1 was previously reported [139, 
170], and could be explained by a direct or indirect antioxidant capacity of DJ-1 [52, 
113, 126-127] or by its action as an oxidative stress sensor [11, 98]. Although a direct 
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antioxidant capacity has been proposed, other evidence showed a weaker antioxidant 
capacity of this protein when compared with peroxidases [103, 113]. Its antioxidant 
activity must be due to other additional factors, such as up-regulation of the 
antioxidant glutathione [126] and stabilization of the transcription factor Nrf2 (a major 
regulator of antioxidant genes) [127]. Some studies suggest a role for intracellular DJ-1 
in the activation of pro-survival [103, 117-120] and inhibition of pro-apoptotic 
signalling pathways [121-123], which could also be related with the neuroprotective 
effect of DJ-1 against H2O2-induced cell death. Therefore, DJ-1-mediated activation of 
Akt and ERK1/2 was tested in this study using a different approach, in which cells were 
incubated with recombinant DJ-1 in the extracellular milieu. 
The mitogen activated protein kinases (MAPK) signalling pathways, in particular 
ERK, contribute to neuronal survival [172]. Moreover, activation of ERK1/2 promotes a 
basal dopaminergic cell survival and protects dopaminergic neurons from oxidative 
stress [173]. On the other hand, Akt, also known as protein kinase B (PKB), is an anti-
apoptotic protein and the PI3K-Akt signalling pathway plays a critical role in 
mediating neuronal survival [174]. In the present study, the activation of the Akt and 
ERK1/2 signalling pathways was observed when SH-SY5Y cells were treated with 1 μM 
of recombinant DJ-1 exogenously added to the medium (an observation that had never 
been reported - Figure 3.9 and Figure 3.10), which complements other studies showing 
the ability of intracellular DJ-1 to activate these pathways [103, 117-120]. 
As the ERK1/2 signalling pathway is crucial to protect cells against oxidative 
stress, the increased ERK1/2 phosphorylation caused by DJ-1 could be related to the 
role of DJ-1 in neuroprotection, as already reported [117]. In fact, that same report 
showed that the neuroprotective capacity of DJ-1 against H2O2-induced cell death was 
depleted when cells were pre-treated with a MEK1/2 inhibitor, suggesting that this DJ-
1 neuroprotective effect was mediated by the activation of this signalling pathway 
[117]. Another study of the same research group, suggested that DJ-1 exerts its 
neuroprotective role by activating the ERK1/2 pathway and suppressing mTOR (a 
major negative regulator of autophagy after phosphorylation by PIK3) in dopaminergic 
cells, leading to enhanced autophagy, more efficient clearance of damaged 
mitochondria, and reduced apoptosis [175]. Antother recent study showed a possible 
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action of DJ-1 in the upregulation of the tyrosine  hydroxylase (TH) (a  rate-limiting  
enzyme  in dopamine  synthesis) gene expression by  activating  its transcriptional  
factor  Nurr1  via  the  ERK1/2  pathway [176]. 
The activation of the Akt and ERK1/2 signalling pathways was already observed 
when SH-SY5Y cells were treated with 1 mM of H2O2 [171], but in this study there is no 
evidence of this activation. Nevertheless, the activation of both signalling pathways 
upon H2O2 treatment, observed in this study when cells were treated with 200 μM of 
H2O2 for 15 minutes (Figure 3.11 and Figure 3.12), was already reported using 300 μM 
of H2O2 after 15 minutes of stimulation in cortical neurons [177]. 
The activation of Akt and ERK1/2 signalling pathways was also observed when 
cells treated with 200 μM of H2O2, in the presence of 1 μM of exogenous recombinant 
DJ-1 (Figure 3.11 and Figure 3.12), and the activation of Akt signalling pathway by DJ-1 
was already been reported using 100 μM of H2O2 at the same time-point (15 min) 
[120]. Although, this has never been tested in the case of activation of ERK1/2 
signalling pathway. These results are an indication that DJ-1 potentiates the activation 
of Akt and ERK1/2 signalling pathways under oxidative stress conditions, which could 
be a very important mechanism of induction of neuroprotection in neuronal cells. 
All these results, although preliminary, open the opportunity for a DJ-1 
mediated neuroprotection after its release from astrocytes by the activation of Akt and 
ERK1/2 signalling pathways in dopaminergic neurons. 
An hypothesis that remains to be clarified is whether DJ-1 secretion from 
astrocytes may further play a neuroprotective role in target neurons after its putative 
uptake. Although there is evidence for DJ-1 uptake by SH-SY5Y cells [143], these results 
could not be confirmed in our study (Figure 3.14 upper panel), hence there is still a 
need for confirmation of this observation from other reports. The recombinant DJ-1 
used in the mentioned study was engineered with an N-terminus GST-tag. However, 
the GST-tag alone was also uptaken by the target cells, which raises the question of 
whether the GST-DJ-1 fusion protein was internalized by cells in a mechanism that 
relied on GST internalization or if it was specific for DJ-1. Moreover, in our 
understanding, GST is a very large tag (≈26 kDa) when compared with the size of DJ-1 
(≈22 kDa in its monomeric form and ≈43 kDa in its dimeric form), hence we chose to 
64 | DISCUSSION 
 
use a smaller tag (a six histidines tag) in the N-terminal of the recombinant protein 
produced in this study. 
Considering the neuroprotective effect of exogenous DJ-1 towards oxidative 
stress insults and that no protein internalization was observed, it was hypothesized 
that DJ-1 could bind and/or activate membrane receptors receptors that might 
transduce signals that could activate Akt and ERK1/2 (Figure 3.9, Figure 3.10, Figure 
3.11 and Figure 3.12). A pull-down assay followed by western-blot analysis did not 
reveal any protein from the membrane-enriched fraction bound to DJ-1 (Figure 3.14 
bottom panel), so there is no evidence for an interaction of DJ-1 with any protein from 
the cytoplasmic membrane. 
Once no evidence indicates DJ-1 internalization or even its interaction with any 
membrane protein, a different strategy was used to find DJ-1 extracellular interactors 
possibly related with DJ-1 neuroprotective mechanisms. Therefore, the conditioned 
medium of SH-SY5Y was used to identify putative DJ-1 extracellular interactors in a 
pull-down assay. Among the identified proteins (Table 3.2), there are some particularly 
interesting ones. The identified proteins: probable carboxypeptidase X1, annexin A2, 
neurocan core protein, vitronectin, fibronectin, nidogen-1 and testican-1 are proteins 
mainly involved in cell adhesion, growth and migration [178-183]. Semaphorin-3C, is 
also involved in the axonal guidance of neurons and cell survival [184]. 
More interestingly, carboxypeptidase E, also identified in this study, seems to 
be involved in the biotransformation of dynorphin A (1-17), an endogenous opioid 
peptide related to the striatonigral pathway [185]. Actually different dynorphin A-
derived peptides were identified in the striatum following a unilateral 6-OHDA-induced 
lesion, correlating them with parkinsonism [185]. Another study showed the 
colocalization of somatostatin protein with prohormone convertase 1, prohormone 
convertase 2 and carboxypeptidase E in rat brain, and somatostatin plays an important 
role in neurological disorders such as Alzheimer’s disease and Huntington’s disease 
[186]. Thus, perhaps DJ-1 has also a role in the striatonigral pathway by its interaction 
with carboxipeptidase E or upstream/downstream molecules. In fact, DJ-1 was found 
in both striatum and substantia nigra [124]. Another possibility is the occurrence of 
the same type of interactions with the proteins already associated with other 
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neurological diseases, including somatostatin protein, prohormone convertase 1, 
prohormone convertase 2 and carboxypeptidase E, giving some clues about similar 
molecular mechanisms possibly related with PD. 
Complement proteins, such as the identified complement C7, are present in 
Lewy bodies in the substantia nigra, with a predominant activation of the classical 
complement cascade, amplifying the proteolytic cascade and opsonizing tissue for 
phagocytosis [187]. Possibly, if DJ-1 can interact with the complement component C7, 
or upstream/downstream molecules, it can be a regulator of the complement cascade. 
Another identified protein was the insulin-like growth factor-binding protein 2 
which has been related to aging, increasing in serum of adults over the age of 60, and 
during starvation periods [188]. This protein seems to be regulated by several 
mechanisms, although the exact mechanism that regulates its concentrations remains 
unclear [188]. One possibility is the involvement of DJ-1 in this regulation mechanism, 
as it is also present in serum [146]. 
In the case of fibronectin, besides its adhesion properties, this protein has been 
implicated in pathological conditions of the central nervous system (CNS) by exerting a 
strong angiogenic influence on endothelial cells, via MAP kinase signalling pathway 
[189]. This signalling pathway seems to be affected by DJ-1, possibly to protect 
neurons from oxidative stress conditions by its activation, as suggested by the results 
presented in this study (Figure 3.10) and as previously reported [117].  
Additionally, mutations in the integral membrane protein 2B, also known as 
BRI2, were found in families with dementia associated with amyloidopathies, linking 
this protein with neurodegenerative disorders [190]. This protein was also detected in 
Lewy neurites in cases of dementia with Lewy bodies and PD, suggesting that it might 
also be involved in Lewy body formation [191]. DJ-1 might also play a role in the 
process of Lewy bodies formation. In fact, DJ-1 has already been reported as a redox-
sensitive molecular chaperone and as inhibitng α-synuclein (a protein present in Lewy 
bodies [11]) aggregate formation [101-102]. 
The identified glia-derived nexin was found to interact with vitronectin (also 
identified in this study), potentiating the neurite-promoting activity [192], so maybe 
these proteins come together (in a complex with DJ-1) in the pull-down assay. On the 
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other hand, the glia-derived nexin, also known as protease nexin-1, is a serine protease 
inhibitor and neurite outgrowth promoter expressed in the rat CNS [193-194]. After 
the induction of substantia nigra and nigrostriatal pathway degeneration with 6-
hydroxydopamine, the de novo synthesis of this protein occurred in the dopamine 
depleted caudate putamen but not in the substantia nigra [193-194]. So, it was 
postulated that the oxidative inactivation of protease nexin-1 in the brain may be 
involved in neurodegeneration [194]. As DJ-1 can have an antioxidant activity [113] it 
might be protecting protease nexin-1 from oxidation. Moreover, the protease nexin-1 
counteracts the cellular effects of thrombin, inhibiting mitogenic activity and inducing 
neurite extension in neurons, leading to the hypothesis that neuronal morphology is 
governed by its interplay [195]. Thrombin activates MAP kinases [196], including the 
phosphoinositide 3-kinase (PI3K) [195], suggesting that thrombin may be involved in 
the neuropathological processes of dopaminergic neuronal cell death that occur in PD 
[196]. Furthermore, there is evidence that injury and disease-related events trigger 
protease nexin-1 production to levels which ultimately abolish the thrombin effects 
[195]. On the other hand, thrombin can have differential effects in vivo, after injury, 
depending on its concentration [195]. For example, at a low concentration, thrombin 
may contribute to the repair processes, and the protease nexin-1 might participate in 
these processes by regulating the levels of active thrombin in the surrounding 
environment of both neurons and astrocytes [195]. As DJ-1 related with MAPK 
signalling pathways activation [as suggested by the results from the present study 
(Figure 3.10) and as previously reported [117]], maybe DJ-1 can also be interacting 
with protease nexin-1 or other up- or down-stream molecules leading to the activation 
of the mentioned signalling pathway. 
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5| CONCLUSIONS 
The main goal of this study was to give some clues about the neuroprotection 
mechanisms of exogenous DJ-1, mimicking its release from astrocytes to the 
extracellular space. To achieve this, a recombinant DJ-1 was produced to exogenously 
add it to cultured SH-SY5Y cells, a model cell line to study Parkinson’s disease. 
This research project allowed the production of a dimeric and functional 
recombinant DJ-1 that conferred neuroprotection to SH-SY5Y cells under H2O2-induced 
oxidative stress conditions, as already reported. 
Moreover, this study provided some preliminary data regarding the activation 
of Akt and ERK1/2 signalling pathways, induced by exogenous DJ-1, under normal or 
oxidative stress conditions. Therefore, the activation of pro-survival signalling 
pathways by DJ-1 remains one of the possible mechanisms of neuroprotection induced 
by this protein. 
Two of the hypotheses raised were the internalization of DJ-1 by neurons, in 
which the protein could exert its neuroprotective effects in the intracellular milieu, or 
alternatively, through membrane receptor-mediated activation of signalling pathways. 
This study did not reveal any evidence for DJ-1 internalization, neither any evidence for 
an interaction with any membrane protein. So, the mechanism by which DJ-1 mediates 
neuroprotection in the extracellular space of cells remains to be clarified. 
The pull-down assay used to identify some possible DJ-1 extracellular 
interactors, allowed the identification of some secreted proteins that can be 
interacting with DJ-1 in the extracellular space mediating its neuroprotective effect. 
These results must be validated in the future by improving the experimental design of 
the approach and by performing complementary assays, such as co-
immunoprecipitation. 
In summary all the results presented in this study contribute to a better 
understanding of the molecular mechanisms leading neuroprotection conferred by DJ-
1 against oxidative stress-induced neuronal death, which is one of the most relevant 
insults in Parkinson’s disease pathology. Hence, these findings may contribute to 
future strategies for the treatment and prevention of the disease. 
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7| SUPPLEMENTARY DATA 
7.1. MOLECULAR SIZE EXCLUSION CHROMATOGRAPHY 
In order to assess if the purified DJ-1 has a homodimer form, which is a 
functional important feature of the protein [112, 128-129], an HPLC-size exclusion 
chromatography was performed. Standards retention times were used to perform a 
calibration curve (Figure 7.1) and the molecular weight of purified DJ-1 was 
determined using the retention time of DJ-1 sample. 
 
 
FIGURE 7.1| HPLC-SIZE EXCLUSION CHROMATOGRAPHY CALIBRATION CURVE. Standards from right to 
left: Blue Dextran (≈2,000 kDa); Ferritin (440 kDa); Aldolase (158 kDa); Conalbumin (75 kDa); Ovalbumin 
(43 kDa); Carbonic Anhydrase (29 kDa); Ribonuclease A (13.7 kDa); Aprotinin (6.5 kDa). The mobile 
phase was PBS with 10% of glycerol (purified recombinant DJ-1 buffer). 
 
Kav is the partition coefficient, which is calculated from the measured elution 
volume (Ve) of each standard protein or protein of interest, using the formula: 
ܭ௔௩ ൌ ௏೐ି௏బ௏೎ି௏బ , where the V0 is the column void volume – elution volume for Blue 
Dextran 2000 –, and Vc is the geometric column volume. 
After having the calibration curve of Kav versus log molecular weight either 
(Figure 7.1), the molecular weight of the protein of interest can be inferred, using its 
calculated Kav. 
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7.2. CELL VIABILITY ASSAYS 
To assess the percentage of viable cells when they were treated different H2O2 
concentrations, different tests can be used, such as the Cell Titer-Glo®Luminescent Cell 
Viability Assay (Promega) and the MTT assay (Life Technologies). The Cell Titer-Glo® 
assay “is a homogeneous method to determine the number of viable cells in culture 
based on quantitation of the ATP present, which signals the presence of metabolically 
active cells”. “The MTT system is a simple, accurate, reproducible means of measuring 
the activity of living cells via mitochondrial dehydrogenase activity”. As in the literature 
the MTT is the most used method, it is need to test if the Cell Titer-Glo® assay 
produces similar results. 
Actually, by performing cell viability experiments, as described in the section 
2.3., using different H2O2 concentrations, the luminescent and absorbance values 
obtained allowed the draw of similar dose-response curves, with similar LD50 values 
(366.6 μM using the MTT assay and 363.4 μM using the Cell Titer-Glo® asay) (Figure 
7.2). Thus, the Cell Titer-Glo® assay was used in further experiments. 
 
 
FIGURE 7.2| COMPARISON OF CELL TITER-GLO® ASSAY WITH MTT ASSAY. SH-SY5Y cells were plated 
and treated with various concentrations of hydrogen peroxide, 4 h after plating. After 24 h, cell viability 
was assessed by the by Cell Titer-Glo® or MTT assay. 
 
As stated in the section 3.5 the inhibition of H2O2-induced cell death by the 
exogenous addition of a recombinant DJ-1 protein was assessed by using different 
H2O2 concentrations in the presence or absence of the purified DJ-1 (1 and 5 μM). The 
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results of the simultaneous treatment of cells with 5 μM of DJ-1 showed a significantly 
increase of the cell viability using 25, 50 and 100 μM of H2O2 (Figure 7.3). 
 
 
 
FIGURE 7.3| PROTECTIVE EFFECT OF RECOMBINANT DJ-1 AGAINST H2O2-INDUCED OXIDATIVE STRESS. 
SH-SY5Y cells were treated with H2O2 (25, 50, 100 and 200 μM) in the presence or absence of 
recombinant His-tagged human DJ-1 protein (5 μM) or vehicle, 4h after plating. After 24 h, cell viability 
was assessed by the Cell Titer-Glo® assay. Data are the mean±SEM of four determinations, based on 
untreated cultures as 100%. Significance (Tukey HSD post hoc comparisons after Two-way ANOVA): *p 
< 0.05, ***p < 0.001 treatment with H2O2 and vehicle vs. treatment with vehicle alone. #p < 0.05 
treatment with H2O2 and DJ-1 vs. corresponding treatment with H2O2 and vehicle.  
 
7.3. INTERNALIZATION OF DJ-1 
One of the major goals of this project was to understand if DJ-1 released from 
astrocytes could be uptake by SH-SY5Y to exert its neuroprotective effect by activating 
intracellular signalling pathways or by a receptor-mediated activation of signalling 
pathways. 
To observe the internalization of the produced recombinant DJ-1, that was 
already reported using a GST-DJ-1 [143], the methodology described in the referred 
paper was used. 
In a first attempt, cells were treated with 100 μM H2O2 and 1 μM DJ-1 
(simultaneously) or with 1 μM of DJ-1, during 4h.  Cellular extracts were performed by 
scraping or shaving cells with trypsin, in order to try to eliminate the recombinant DJ-1 
that could be bound to the cellular membrane, and the western-blot was performed 
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using the mouse Anti-His Tag TM0243 (1:5,000) (GenScript, USA), as described in 
section 2.6.3. (Figure 7.4). 
 
 
FIGURE 7.4| INTERNALIZATION OF 6-HIS-DJ-1. SH-SY5Y cells were treated with 100 μM H2O2 and 1 μM 
DJ-1 (simultaneously) or with μM of DJ-1, for 4h.  Cellular extracts were performed by scraping or 
shaving cells with trypsin and the western-blot was performed using an anti-His antibody. The positive 
control is the purified DJ-1 and the negative control is a SH-SY5Y protein extract. 
 
There is no evidence for a DJ-1 internalization by SH-SY5Y cells, as there is no 
band at approximately 25 kDa (except in the case of the positive control), 
corresponding to the recombinant protein. There are bands at ≈50 kDa, which could 
correspond to the dimeric form of the protein, but all samples were denatured with 
sample buffer with DTT, so all contained proteins must be unfolded and these bands 
appeared in all the conditions, including in the negative control. So, these are 
unspecific bands. 
Another test was performed using 200 μM H2O2 and 1 μM DJ-1 (simultaneously) 
or 1 μM of DJ-1, and using DMEM with 0.1 or 10% FBS.  The objective of this test was 
to understand if the oxidative stress stimulus wasn’t enough (although an oxidative 
stress independent uptake was described [143]) and if the FBS was interfering with the 
test. Cellular extracts were performed by scraping and the western-blot was 
performed using the same anti-His antibody (Figure 7.5). 
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FIGURE 7.5| INTERNALIZATION OF 6-HIS-DJ-1. SH-SY5Y cells were treated with 200 μM H2O2 and 1 μM 
DJ-1 or 1 μM of DJ-1, and using DMEM with 0.1 or 10% FBS, for 4h.  Cellular extracts were performed 
by scraping or shaving cells with trypsin and the western-blot was performed using an anti-His 
antibody. The positive control is the purified DJ-1, the positive control II is an SH-SY5Y protein extract 
with DJ-1, and the negative control is an SH-SY5Y protein extract. 
 
Again, there is no evidence for a DJ-1 uptake by SH-SY5Y cells, because there is 
no band at approximately 25 kDa, corresponding to the recombinant protein (except in 
both positive controls). There are unspesific bands at ≈60 kDa in all the conditions, 
including control conditions. 
One hypothesis for the absence of DJ-1 signal in the performed western-blots is 
the lower amount of internalized protein that enables its detection by this technique. 
Thus, an enrichment process was performed to try to concentrate the final sample 
with the possibly internalized protein (Figure 7.6). For this, an His-trap resin was used 
because the produced DJ-1 had an 6-His tag with affinity for this resin. The incubation 
of protein extracts with the His-trap resin and the further resin processing was 
performed as described on section 2.6.2. 
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FIGURE 7.6| INTERNALIZATION OF 6-HIS-DJ-1. SH-SY5Y cells were treated with 200 μM H2O2 and 1 μM 
DJ-1 or with μM of DJ-1, for 4h and using DMEM with 0.1 % FBS. Cellular extracts were performed by 
shaving cells with trypsin and incubated with the His-trap resin. Western-blot was performed with the 
fraction of eluted proteins using an anti-DJ-1 antibody (KAM-SA100). The positive control is an SH-SY5Y 
protein extract with DJ-1, and the negative control is an SH-SY5Y protein extract. 
 
Even using the enrichment strategy there is no evidence for a DJ-1 uptake by 
SH-SY5Y cells, because there is no band at approximately 25 kDa, corresponding to the 
recombinant protein (except in the positive control) (Figure 7.6). There are unspesific 
bands at ≈75 and ≈150 kDa in all the conditions, including control conditions. 
 
A final experiment was performed to try to observe the internalization of 
exogenous DJ-1 in SH-SY5Y cells or its interaction with its membrane proteins 
(described in section 2.6.). This experiment involves an ultracentrifugation step to have 
two protein fractions: one enriched in membrane proteins and other enriched in 
cytosolic proteins. So, it is necessary to show the efficiency of this enrichment step. For 
that, membranes corresponding to proteins that did not bind to the His trap resin 
(Figure 3.13) were stripped and reprobed against a mouse Anti-GAPDH antibody 
(1:500) (sc-47724) (Santa Cruz) or a mouse Anti-Transferrin Receptor (1:500) (13-6800) 
(Invitrogen). The results showed a good enrichment of membrane proteins in the 
membrane enriched fraction and a good enrichment of cytosolic proteins in the 
cytosolic enriched fraction (Figure 7.7 and Figure 7.8), as there is a higher amount of 
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GAPDH (a cytosolic protein) in the cytosolic enriched fraction than in the membrane 
enriched fraction (Figure 7.7), and a higher amount of the transferring receptor (a 
membrane protein receptor) in the membrane enriched fraction than in the cytosolic 
enriched fraction (Figure 7.8). 
 
 
FIGURE 7.7| CYTOSOLIC PROTEINS ENRICHMENT. Control of the cytosolic proteins enrichment in the 
cytosolic enriched fraction. Western-blot performed with cytosolic and membrane enriched fractions using 
an anti-GAPDH antibody. The negative control is an SH-SY5Y total protein extract and the positive control is 
the same extract with the addition of 0.6 μg of the recombinant DJ-1. 
 
 
FIGURE 7.8| MEMBRANE PROTEINS ENRICHMENT. Control of the membrane proteins enrichment in the 
membrane enriched fraction. Western-blot performed with cytosolic and membrane enriched fractions 
using an anti-Transferrin Receptor antibody. The negative control is an SH-SY5Y total protein extract and the 
positive control is the same extract with the addition of 0.6 μg of the recombinant DJ-1. 
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7.4. EXTRACELLULAR AND MEMBRANE INTERACTORS 
As no evidence for a DJ-1 uptake was found, strategies to find extracellular 
interactors were taken. 
One of the strategies used was the use of a crosslinker (DTSSP) (Thermo Fisher 
Scientific) to try to crosslink extracellular proteins with the recombinant DJ-1 
exogenously added. For that, cells cultured in 21 cm2 plates (Corning) were incubated 
with 1 μM of recombinant DJ-1 in sodium medium (140 mM NaCl, 5 mM KCl, 1 mM 
CaCl2, 1 mM MgCl2, 10 mM glucose, 10 mM HEPES-Na+, pH 7.4) for 1h at 37 °C. After 
this time period, the crosslinker was added (2 mM of DTSSP) and incubated for 30 min 
at the same temperature. The crosslinker reaction was quenched by adding 20 mM of 
Tris. 
The culture medium was collected and concentrated by rotary evaporation, 
using the Concentrator Plus (Eppendorf) at 60 °C and then using concentrators with a 
cut-off of 5 kDa (500 μL) (Sartorius). To try to observe if DJ-1 was crosslinked with any 
membrane protein, cellular protein extracts were produced as described on section 
2.5.2. with and without DTT (in RIPA  buffer and sample buffer), because DTT cleaves 
the crosslinker, and both conditions are desired (cleaved and not cleaved). Culture 
mediums and protein extracts were incubated with the His-trap resin as described on 
section 2.6.2. The resin processing after the incubation is also described in the same 
section. 
Samples were electrophoretically separated on pre-cast AnyKD™ SDS-
polyacrylamide gels (Bio-Rad) and stained with silver. For western-blot samples were 
electrophoretically separated on pre-cast 12 % SDS-polyacrylamide gels (Bio-Rad) and 
western-bloted using the goat Anti-DJ-1 C-16 antibody (1:200) (Santa Cruz 
Biotechnology, Inc. (sc-27006) (Heidelberg, Germany), as described in section 2.6.3. 
There are some evidence for a possible interaction of DJ-1 with extracellular 
proteins, as there are protein bands in the gel stained with silver, when the crossliker 
wasn’t cleaved with DTT (Figure 7.9, A). Moreover, the western-blot shows the 
presence of DJ-1 at higher molecular weights (when the crosslinker wasn’t cleaved), 
which can indicate the linkage between the interest protein and other proteins. When 
the crosslinker was cleaved, the bands corresponding to DJ-1 appeared at 50 or 25 
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kDa, which may be do the incomplete cleavage of the crosslinker in these samples 
(Figure 7.9, B).  
 
 
FIGURE 7.9| EXTRACELLULAR INTERACTORS – CULTURE MEDIUMS. A – Silverstained polyacrilamide gel. 
The positive control is the recombinant DJ-1. B – Western-blot. The positive control is the recombinant DJ-1. 
 
On the other hand, there are no evidence for a DJ-1 interaction with any 
membrane protein, as there is no band corresponding to DJ-1 (Figure 7.10, B), except 
in the positive control. 
 
 
FIGURE 7.10| EXTRACELLULAR INTERACTORS – CELLULAR PROTEIN EXTRACTS. A – Silverstained polyacrilamide 
gel. The positive control is the recombinant DJ-1. B – Western-blot. The positive control is the recombinant DJ-
1. 
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Although, by performing some controls of the experiment, it seems that the 
evidence for a DJ-1 interaction with extracellular proteins are only due to the 
interaction of DJ-1 with itself, or remaining serum proteins, as cells (or the plate 
without cells) were washed only once with sodium medium (Figure 7.11). The 
performed controls were: 
1. With cells in culture: in the presence or absence of 1 μM of the 
recombinant DJ-1; 
2. Without cells in culture: in the presence or absence of 1 μM of the 
recombinant DJ-1. 
 
 
FIGURE 7.11| EXTRACELLULAR INTERACTORS – CELLULAR PROTEIN EXTRACTS. A and C – Silverstained 
polyacrilamide gel. The positive control is the recombinant DJ-1. B and D – Western-blot. The positive 
control is the recombinant DJ-1. 
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Another strategy was then taken, a pull-down assay (described on section 2.7). 
As previously stated, some proteins were found both in the pull-down assay 
performed using the recombinant protein bound to the His-trap resin, and using the 
His-trap resin without the addition of the recombinant protein. Furthermore, as one of 
these found proteins was the endogenous DJ-1 protein, maybe some of these 
identified proteins can be interacting not only with the His-trap resin, but also with the 
endogenous DJ-1. So, some of these proteins could also be DJ-1 interactors in the 
extracellular space Table 7.1. These results must be validated in the future by refining 
the experimental procedure. One of the possible improvements of the method is the 
increase of the number of washing steps. 
 
TABLE 7.1| PROTEINS FROM THE CONDITIONED MEDIUM PULL-DOWNED AGAINST DJ-1 BOUND TO 
THE HIS-TRAP RESIN OR AGAINST THE HIS-TRAP RESIN WITHOUT DJ-1 (CONTROL). 
Protein ID with DJ-1 without DJ-1 
Name Accessions Specie Unique Peptides 
Unique 
Peptides 
Protein DJ-1  Q99497|PARK7_HUMAN Homo sapiens  172 22 
Secretogranin-1  P05060|SCG1_HUMAN Homo sapiens  26 31 
Peroxidasin homolog  Q92626|PXDN_HUMAN Homo sapiens  31 29 
Neurosecretory protein 
VGF  O15240|VGF_HUMAN Homo sapiens  27 25 
Agrin  O00468|AGRIN_HUMAN Homo sapiens  25 24 
EMILIN-1  Q9Y6C2|EMIL1_HUMAN Homo sapiens  21 23 
Sulfhydryl oxidase 1  O00391|QSOX1_HUMAN Homo sapiens  16 18 
Insulin-like growth factor-
binding protein-like 1  Q8WX77|IBPL1_HUMAN Homo sapiens  7 18 
Chromogranin-A  P10645|CMGA_HUMAN Homo sapiens  13 17 
Plasma serine protease 
inhibitor  P05154|IPSP_HUMAN Homo sapiens  16 15 
Follistatin-related protein 5  Q8N475|FSTL5_HUMAN Homo sapiens  10 13 
Laminin subunit alpha-5  O15230|LAMA5_HUMAN Homo sapiens  9 12 
Tenascin  P24821|TENA_HUMAN Homo sapiens  7 12 
Tissue-type plasminogen 
activator  P00750|TPA_HUMAN Homo sapiens  14 11 
Laminin subunit beta-1  P07942|LAMB1_HUMAN Homo sapiens  6 10 
Lactotransferrin  P02788|TRFL_HUMAN Homo sapiens  8 9 
Phospholipid transfer 
protein  P55058|PLTP_HUMAN Homo sapiens  7 8 
A disintegrin and 
metalloproteinase with 
thrombospondin motifs 9  
Q9P2N4|ATS9_HUMAN Homo sapiens  8 8 
Semaphorin-3A  Q14563|SEM3A_HUMAN Homo sapiens  5 7 
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Peptidyl-prolyl cis-trans 
isomerase A  P62937|PPIA_HUMAN Homo sapiens  7 6 
Procollagen C-
endopeptidase enhancer 1  Q15113|PCOC1_HUMAN Homo sapiens  7 6 
Protein kinase C-binding 
protein NELL2  Q99435|NELL2_HUMAN Homo sapiens  5 6 
Fibulin-1  P23142|FBLN1_HUMAN Homo sapiens  5 5 
Thrombospondin type-1 
domain-containing protein 
7A  
Q9UPZ6|THS7A_HUMAN Homo sapiens  4 5 
A disintegrin and 
metalloproteinase with 
thrombospondin motifs 19  
Q8TE59|ATS19_HUMAN Homo sapiens  6 4 
Laminin subunit gamma-1  P11047|LAMC1_HUMAN Homo sapiens  6 4 
Lumican  P51884|LUM_HUMAN Homo sapiens  3 4 
Clusterin  P10909|CLUS_HUMAN Homo sapiens  6 3 
Dickkopf-related protein 1  O94907|DKK1_HUMAN Homo sapiens  3 3 
Galectin-3-binding protein  Q08380|LG3BP_HUMAN Homo sapiens  5 3 
Galectin-1  P09382|LEG1_HUMAN Homo sapiens  2 3 
Secreted frizzled-related 
protein 3  Q92765|SFRP3_HUMAN Homo sapiens  2 3 
Collagen alpha-1(VI) chain  P12109|CO6A1_HUMAN Homo sapiens  2 2 
Complement C1q tumor 
necrosis factor-related 
protein 3  
Q9BXJ4|C1QT3_HUMAN Homo sapiens  1 1 
 
Non-secreted proteins that putatively interacts with the exogenous DJ-1 in the 
extracellular space of cells (only identified in the pull-down assay against the 
recombinant DJ-1 bound to the His-trap Resin) are presented in the table below. To 
the aim of the work these proteins weren’t relevant, but it is possible that due to the 
death of some cells, some intracellular proteins were found. Among these proteins can 
be some interesting ones, so these results must be analysed in the future and 
approaches using total proteins extracts can also be performed to try to identify DJ-1 
intracellular interactors. 
 
TABLE 7.2| NON-SECRETED PROTEINS FROM THE CONDITIONED MEDIUM PULL-DOWNED WITH DJ-1. 
Name Accessions Specie Unique Peptides 
Tubulin alpha-1B chain  P68363|TBA1B_HUMAN Homo sapiens  16 
78 kDa glucose-regulated protein  P11021|GRP78_HUMAN Homo sapiens  16 
ATP synthase subunit beta, 
mitochondrial  P06576|ATPB_HUMAN Homo sapiens  15 
Transketolase  P29401|TKT_HUMAN Homo sapiens  15 
ATP-citrate synthase  P53396|ACLY_HUMAN Homo sapiens  12 
 SUPPLEMENTARY DATA | 93 
 
Vimentin  P08670|VIME_HUMAN Homo sapiens  10 
T-complex protein 1 subunit gamma  P49368|TCPG_HUMAN Homo sapiens  10 
Heat shock 70 kDa protein 1  P08107|HSP71_HUMAN Homo sapiens  8 
Tryptophan--tRNA ligase, 
cytoplasmic  P23381|SYWC_HUMAN Homo sapiens  8 
Stress-70 protein, mitochondrial  P38646|GRP75_HUMAN Homo sapiens  7 
Nucleoside diphosphate kinase B  P22392|NDKB_HUMAN Homo sapiens  7 
Histone H4  P62805|H4_HUMAN Homo sapiens  6 
Calsyntenin-3  Q9BQT9|CSTN3_HUMAN Homo sapiens  6 
Pleiotropic regulator 1  O43660|PLRG1_HUMAN Homo sapiens  6 
Puromycin-sensitive 
aminopeptidase  P55786|PSA_HUMAN Homo sapiens  6 
Plastin-3  P13797|PLST_HUMAN Homo sapiens  6 
Tubulin beta-3 chain  Q13509|TBB3_HUMAN Homo sapiens  6 
Histone H2A.x  P16104|H2AX_HUMAN Homo sapiens  5 
T-complex protein 1 subunit delta  P50991|TCPD_HUMAN Homo sapiens  5 
Hypoxia up-regulated protein 1  Q9Y4L1|HYOU1_HUMAN Homo sapiens  5 
Spectrin beta chain, brain 1  Q01082|SPTB2_HUMAN Homo sapiens  3 
Cytosolic non-specific dipeptidase  Q96KP4|CNDP2_HUMAN Homo sapiens  5 
Histidine triad nucleotide-binding 
protein 1  P49773|HINT1_HUMAN Homo sapiens  5 
Septin-7  Q16181|SEPT7_HUMAN Homo sapiens  5 
Peroxiredoxin-5, mitochondrial  P30044|PRDX5_HUMAN Homo sapiens  4 
Septin-2  Q15019|SEPT2_HUMAN Homo sapiens  4 
Cadherin-2  P19022|CADH2_HUMAN Homo sapiens  4 
Tubulin alpha-1A chain Q71U36|TBA1A_HUMAN Homo sapiens  4 
Immunity-related GTPase family Q 
protein  Q8WZA9|IRGQ_HUMAN Homo sapiens  4 
DNA-(apurinic or apyrimidinic site) 
lyase  P27695|APEX1_HUMAN Homo sapiens  4 
RuvB-like 2  Q9Y230|RUVB2_HUMAN Homo sapiens  4 
Enhancer of rudimentary homolog  P84090|ERH_HUMAN Homo sapiens  4 
Protein transport protein Sec23A  Q15436|SC23A_HUMAN Homo sapiens  4 
Heterogeneous nuclear 
ribonucleoproteins C1/C2  P07910|HNRPC_HUMAN Homo sapiens  3 
Splicing factor 3B subunit 3  Q15393|SF3B3_HUMAN Homo sapiens  3 
14-3-3 protein theta  P27348|1433T_HUMAN Homo sapiens  3 
Neutral alpha-glucosidase AB  Q14697|GANAB_HUMAN Homo sapiens  3 
Glycine--tRNA ligase  P41250|SYG_HUMAN Homo sapiens  3 
Actin, muscle-type A2  P68032|ACTC_HUMAN Homo sapiens  3 
Tubulin beta-4 chain  Q3ZCM7|TBB8_HUMAN Homo sapiens  3 
Splicing factor 1  Q15637|SF01_HUMAN Homo sapiens  3 
Retinol-binding protein 1  P09455|RET1_HUMAN Homo sapiens  3 
Profilin-2  P35080|PROF2_HUMAN Homo sapiens  3 
Actin-related protein 3  P61158|ARP3_HUMAN Homo sapiens  3 
Glucose-6-phosphate 1-
dehydrogenase  P11413|G6PD_HUMAN Homo sapiens  3 
Poly [ADP-ribose] polymerase 1  P09874|PARP1_HUMAN Homo sapiens  3 
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SUMO-activating enzyme subunit 2  Q9UBT2|SAE2_HUMAN Homo sapiens 3 
Proteasome activator complex 
subunit 1  Q06323|PSME1_HUMAN Homo sapiens 3 
40S ribosomal protein S10  P46783|RS10_HUMAN Homo sapiens  3 
60S acidic ribosomal protein P0  P05388|RLA0_HUMAN Homo sapiens  3 
Bone morphogenetic protein 1  P13497|BMP1_HUMAN Homo sapiens  3 
Nucleobindin-1  Q02818|NUCB1_HUMAN Homo sapiens  3 
40S ribosomal protein S20  P60866|RS20_HUMAN Homo sapiens  3 
GTP-binding nuclear protein Ran  P62826|RAN_HUMAN Homo sapiens  3 
Isocitrate dehydrogenase [NADP] 
cytoplasmic  O75874|IDHC_HUMAN Homo sapiens  3 
Paraspeckle component 1  Q8WXF1|PSPC1_HUMAN Homo sapiens  3 
Mannosyl-oligosaccharide 1,2-alpha-
mannosidase IA  P33908|MA1A1_HUMAN Homo sapiens  3 
Small nuclear ribonucleoprotein Sm 
D3  P62318|SMD3_HUMAN Homo sapiens  3 
Serine/threonine-protein 
phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform  
P30153|2AAA_HUMAN Homo sapiens  2 
26S proteasome non-ATPase 
regulatory subunit 1  Q99460|PSMD1_HUMAN Homo sapiens  2 
Cellular retinoic acid-binding protein 
1  P29762|RABP1_HUMAN Homo sapiens  2 
Trifunctional purine biosynthetic 
protein adenosine-3  P22102|PUR2_HUMAN Homo sapiens  2 
Biliverdin reductase A  P53004|BIEA_HUMAN Homo sapiens  2 
Acetyl-CoA acetyltransferase, 
mitochondrial  P24752|THIL_HUMAN Homo sapiens  2 
Coronin-1B  Q9BR76|COR1B_HUMAN Homo sapiens  2 
Kinesin-1 heavy chain  P33176|KINH_HUMAN Homo sapiens  2 
Fermitin family homolog 2  Q96AC1|FERM2_HUMAN Homo sapiens  2 
Serine hydroxymethyltransferase, 
mitochondrial  P34897|GLYM_HUMAN Homo sapiens  2 
Septin-9  Q9UHD8|SEPT9_HUMAN Homo sapiens  2 
Nuclear autoantigenic sperm protein  P49321|NASP_HUMAN Homo sapiens  2 
Aldose reductase  P15121|ALDR_HUMAN Homo sapiens  2 
Gamma-enolase  P09104|ENOG_HUMAN Homo sapiens  2 
Beta-1,4-galactosyltransferase 5  O43286|B4GT5_HUMAN Homo sapiens  2 
ALK tyrosine kinase receptor  Q9UM73|ALK_HUMAN Homo sapiens  2 
PDZ and LIM domain protein 5  Q96HC4|PDLI5_HUMAN Homo sapiens  2 
DNA replication licensing factor 
MCM2  P49736|MCM2_HUMAN Homo sapiens  2 
60S ribosomal protein L27  P61353|RL27_HUMAN Homo sapiens  2 
Protein mago nashi homolog  P61326|MGN_HUMAN Homo sapiens  2 
Polyadenylate-binding protein 1 P11940|PABP1_HUMAN Homo sapiens  2 
N-acetyl-D-glucosamine kinase  Q9UJ70|NAGK_HUMAN Homo sapiens  2 
Histone H2A.V  Q71UI9|H2AV_HUMAN Homo sapiens  1 
Nuclear mitotic apparatus protein 1  Q14980|NUMA1_HUMAN Homo sapiens  1 
Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, P31040|DHSA_HUMAN Homo sapiens  1 
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mitochondrial  
Probable ATP-dependent RNA 
helicase DDX17  Q92841|DDX17_HUMAN Homo sapiens  1 
DNA replication licensing factor 
mcm4  P33991|MCM4_HUMAN Homo sapiens  1 
40S ribosomal protein S13  P62277|RS13_HUMAN Homo sapiens  1 
AP-2 complex subunit beta  P63010|AP2B1_HUMAN Homo sapiens  1 
Glucosylceramidase  P04062|GLCM_HUMAN Homo sapiens  1 
Alpha-centractin  P61163|ACTZ_HUMAN Homo sapiens  1 
Polyubiquitin  P62987|RL40_HUMAN Homo sapiens  1 
Barrier-to-autointegration factor  O75531|BAF_HUMAN Homo sapiens  1 
BolA-like protein 2  Q9H3K6|BOLA2_HUMAN Homo sapiens  1 
Myosin light polypeptide 6  P60660|MYL6_HUMAN Homo sapiens  1 
Platelet-activating factor 
acetylhydrolase IB subunit gamma  P68402|PA1B2_HUMAN Homo sapiens  1 
Alcohol dehydrogenase class-3  P11766|ADHX_HUMAN Homo sapiens  1 
Peptidyl-glycine alpha-amidating 
monooxygenase  P19021|AMD_HUMAN Homo sapiens  1 
Melanoma-associated antigen 10  P43363|MAGAA_HUMAN Homo sapiens  1 
Porphobilinogen deaminase  P08397|HEM3_HUMAN Homo sapiens  1 
Acetyl-CoA acetyltransferase, 
cytosolic  Q9BWD1|THIC_HUMAN Homo sapiens  1 
Mitochondrial fission 1 protein  Q9Y3D6|FIS1_HUMAN Homo sapiens  1 
Stomatin-like protein 2  Q9UJZ1|STML2_HUMAN Homo sapiens  1 
Small nuclear ribonucleoprotein-
associated protein B'  Q92611|EDEM1_HUMAN Homo sapiens  1 
26S protease regulatory subunit 6A  P17980|PRS6A_HUMAN Homo sapiens  1 
Polymerase delta-interacting 
protein 2  Q9Y2S7|PDIP2_HUMAN Homo sapiens  1 
 
Moreover, as in the case of secreted proteins, there are also non-secreted 
proteins identified in both pull-down fractions, using the recombinant DJ-1 bound to 
the His-trap resin, and using the His-trap resin without the addition of the recombinant 
protein (Table 7.3). Again, these proteins weren’t relevant to the aim of the work, but 
among these proteins can be some interesting ones, so these results must be analysed 
in the future and the technical procedure must be improved to avoid the possible 
effect of the binding of the endogenous DJ-1 to the His-trap resin. 
 
 
 
 
96 | SUPPLEMENTARY DATA 
 
TABLE 7.3| NON-SECRETED PROTEINS FROM THE CONDITIONED MEDIUM PULL-DOWNED AGAINST DJ-
1 BOUND TO THE HIS-TRAP RESIN OR AGAINST THE HIS-TRAP RESIN WITHOUT DJ-1 (CONTROL). 
Protein ID with DJ-1 without DJ-1 
Name Accessions Specie Unique Peptides 
Unique 
Peptides 
Prelamin-A/C  P02545|LMNA_HUMAN Homo sapiens  32 37 
Heat shock cognate 71 kDa 
protein  P11142|HSP7C_HUMAN Homo sapiens  26 27 
60 kDa heat shock protein, 
mitochondrial  P10809|CH60_HUMAN Homo sapiens  23 27 
Calsyntenin-1  O94985|CSTN1_HUMAN Homo sapiens  20 27 
Elongation factor 2  P13639|EF2_HUMAN Homo sapiens  31 26 
Pyruvate kinase isozymes M1/M2  P14618|KPYM_HUMAN Homo sapiens  26 23 
Protein DJ-1  Q99497|PARK7_HUMAN Homo sapiens  172 22 
Alpha-enolase  P06733|ENOA_HUMAN Homo sapiens  18 21 
Splicing factor, proline- and 
glutamine-rich  P23246|SFPQ_HUMAN Homo sapiens  16 18 
Non-POU domain-containing 
octamer-binding protein  Q15233|NONO_HUMAN Homo sapiens  16 17 
T-complex protein 1 subunit theta  P50990|TCPQ_HUMAN Homo sapiens  12 16 
T-complex protein 1 subunit zeta  P40227|TCPZ_HUMAN Homo sapiens  17 14 
Dopamine beta-hydroxylase  P09172|DOPO_HUMAN Homo sapiens  8 14 
Filamin-A  P21333|FLNA_HUMAN Homo sapiens  23 13 
Heat shock protein HSP 90-beta  P08238|HS90B_HUMAN Homo sapiens  17 13 
Fascin  Q16658|FSCN1_HUMAN Homo sapiens  12 13 
Calsyntenin-2  Q9H4D0|CSTN2_HUMAN Homo sapiens  13 13 
Glyceraldehyde-3-phosphate 
dehydrogenase  P04406|G3P_HUMAN Homo sapiens  14 12 
Heterogeneous nuclear 
ribonucleoprotein K  P61978|HNRPK_HUMAN Homo sapiens  13 12 
T-complex protein 1 subunit beta  P78371|TCPB_HUMAN Homo sapiens  10 12 
Peroxiredoxin-6  P30041|PRDX6_HUMAN Homo sapiens  3 12 
Spliceosome RNA helicase Ddx39b  Q13838|DX39B_HUMAN Homo sapiens  11 11 
Alpha-actinin-4  O43707|ACTN4_HUMAN Homo sapiens  12 11 
Isochorismatase domain-
containing protein 1  Q96CN7|ISOC1_HUMAN Homo sapiens  7 11 
Clathrin heavy chain 1  Q00610|CLH1_HUMAN Homo sapiens  22 10 
Alpha-1,6-mannosylglycoprotein 
6-beta-N-
acetylglucosaminyltransferase A  
Q09328|MGT5A_HUMAN Homo sapiens  10 10 
Glutathione S-transferase P  P09211|GSTP1_HUMAN Homo sapiens  6 10 
Phosphoglycerate kinase 1  P00558|PGK1_HUMAN Homo sapiens  6 10 
Protein disulfide-isomerase A6  Q15084|PDIA6_HUMAN Homo sapiens  10 9 
Fructose-bisphosphate aldolase A  P04075|ALDOA_HUMAN Homo sapiens  9 9 
Lissencephaly-1 homolog  P43034|LIS1_HUMAN Homo sapiens  9 9 
Heterogeneous nuclear 
ribonucleoproteins A2/B1  P22626|ROA2_HUMAN Homo sapiens  8 9 
Dihydropyrimidinase-related 
protein 2  Q16555|DPYL2_HUMAN Homo sapiens  11 8 
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6-phosphogluconate 
dehydrogenase, decarboxylating  P52209|6PGD_HUMAN Homo sapiens  12 8 
Interleukin enhancer-binding 
factor 2  Q12905|ILF2_HUMAN Homo sapiens  8 8 
Creatine kinase B-type  P12277|KCRB_HUMAN Homo sapiens  8 8 
L-lactate dehydrogenase B chain  P07195|LDHB_HUMAN Homo sapiens  7 8 
Rab GDP dissociation inhibitor 
beta  P50395|GDIB_HUMAN Homo sapiens  8 8 
Multifunctional protein ADE2  P22234|PUR6_HUMAN Homo sapiens  7 8 
Peroxiredoxin-1  Q06830|PRDX1_HUMAN Homo sapiens  4 8 
Fatty acid synthase  P49327|FAS_HUMAN Homo sapiens  19 7 
Splicing factor 3B subunit 4  Q15427|SF3B4_HUMAN Homo sapiens  9 7 
Spectrin alpha chain, brain  Q13813|SPTA2_HUMAN Homo sapiens  14 7 
Heterogeneous nuclear 
ribonucleoprotein L  P14866|HNRPL_HUMAN Homo sapiens  8 7 
DNA damage-binding protein 1  Q16531|DDB1_HUMAN Homo sapiens  10 7 
Interleukin enhancer-binding 
factor 3  Q12906|ILF3_HUMAN Homo sapiens  6 7 
T-complex protein 1 subunit 
epsilon  P48643|TCPE_HUMAN Homo sapiens  9 7 
Polypyrimidine tract-binding 
protein 1  P26599|PTBP1_HUMAN Homo sapiens  6 7 
Peroxiredoxin-2  P32119|PRDX2_HUMAN Homo sapiens  6 7 
Amyloid-like protein 1  P51693|APLP1_HUMAN Homo sapiens  6 7 
Heterogeneous nuclear 
ribonucleoprotein A1  P09651|ROA1_HUMAN Homo sapiens  3 7 
Putative pre-mRNA-splicing factor 
ATP-dependent RNA helicase 
DHX15  
O43143|DHX15_HUMAN Homo sapiens  3 7 
Noelin  Q99784|NOE1_HUMAN Homo sapiens  4 7 
Adenylyl cyclase-associated 
protein 1  Q01518|CAP1_HUMAN Homo sapiens  9 7 
Creatine kinase U-type, 
mitochondrial  P12532|KCRU_HUMAN Homo sapiens  8 6 
Profilin-1  P07737|PROF1_HUMAN Homo sapiens  7 6 
Ubiquitin-like modifier-activating 
enzyme 1  P22314|UBA1_HUMAN Homo sapiens  11 6 
T-complex protein 1 subunit alpha  P17987|TCPA_HUMAN Homo sapiens  10 6 
Cytosolic acyl coenzyme A 
thioester hydrolase  O00154|BACH_HUMAN Homo sapiens  6 6 
Malate dehydrogenase, 
mitochondrial  P40926|MDHM_HUMAN Homo sapiens  5 6 
Transitional endoplasmic 
reticulum ATPase  P55072|TERA_HUMAN Homo sapiens  9 5 
Cofilin-1  P23528|COF1_HUMAN Homo sapiens  6 5 
Eukaryotic translation initiation 
factor 5A-1  P63241|IF5A1_HUMAN Homo sapiens  5 5 
Vinculin  P18206|VINC_HUMAN Homo sapiens  7 5 
Eukaryotic initiation factor 4A-I  P60842|IF4A1_HUMAN Homo sapiens  5 5 
T-complex protein 1 subunit eta  Q99832|TCPH_HUMAN Homo sapiens  4 5 
X-ray repair cross-complementing 
protein 6  P12956|XRCC6_HUMAN Homo sapiens  6 5 
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Heterogeneous nuclear 
ribonucleoprotein D0  Q14103|HNRPD_HUMAN Homo sapiens  4 5 
Heterogeneous nuclear 
ribonucleoprotein Q  O60506|HNRPQ_HUMAN Homo sapiens  3 5 
Talin-1  Q9Y490|TLN1_HUMAN Homo sapiens  4 5 
Aldehyde dehydrogenase family 
16 member A1  Q8IZ83|A16A1_HUMAN Homo sapiens  3 5 
Sia-alpha-2,3-Gal-beta-1,4-
GlcNAc-R:alpha 2,8-
sialyltransferase  
O43173|SIA8C_HUMAN Homo sapiens  4 5 
Far upstream element-binding 
protein 1  Q96AE4|FUBP1_HUMAN Homo sapiens  2 5 
ATP synthase subunit alpha, 
mitochondrial  P25705|ATPA_HUMAN Homo sapiens  12 4 
Dihydropyrimidinase-related 
protein 3  Q14195|DPYL3_HUMAN Homo sapiens  11 4 
Ubiquitin-conjugating enzyme E2 
N  P61088|UBE2N_HUMAN Homo sapiens  6 4 
Endoplasmin  P14625|ENPL_HUMAN Homo sapiens  7 4 
Protein disulfide-isomerase A3  P30101|PDIA3_HUMAN Homo sapiens  3 4 
Thrombospondin-3  P49746|TSP3_HUMAN Homo sapiens  3 4 
Plasminogen activator inhibitor 1 
RNA-binding protein  Q8NC51|PAIRB_HUMAN Homo sapiens  7 4 
Cysteine-rich protein 2  P52943|CRIP2_HUMAN Homo sapiens  2 4 
Heat shock 70 kDa protein 4  P34932|HSP74_HUMAN Homo sapiens  3 4 
Actin-related protein 2/3 complex 
subunit 1B  O15143|ARC1B_HUMAN Homo sapiens  2 4 
Protein FAM49B  Q9NUQ9|FA49B_HUMAN Homo sapiens  1 4 
Elongation factor 1-alpha 2  Q05639|EF1A2_HUMAN Homo sapiens  12 3 
Importin subunit beta-1  Q14974|IMB1_HUMAN Homo sapiens  8 3 
Adenosylhomocysteinase  P23526|SAHH_HUMAN Homo sapiens  5 3 
Microtubule-associated protein 
1B  P46821|MAP1B_HUMAN Homo sapiens  8 3 
Serpin H1  P50454|SERPH_HUMAN Homo sapiens  4 3 
Elongation factor Tu, 
mitochondrial  P49411|EFTU_HUMAN Homo sapiens  3 3 
Peptidyl-prolyl cis-trans 
isomerase FKBP4  Q02790|FKBP4_HUMAN Homo sapiens  6 3 
Ubiquitin-conjugating enzyme E2 
variant 1  Q13404|UB2V1_HUMAN Homo sapiens  3 3 
Histone H2B type 1-L  Q99880|H2B1L_HUMAN Homo sapiens  2 3 
ATP-dependent RNA helicase 
DDX1  Q92499|DDX1_HUMAN Homo sapiens  3 3 
RuvB-like 1  Q9Y265|RUVB1_HUMAN Homo sapiens  6 2 
40S ribosomal protein SA  P08865|RSSA_HUMAN Homo sapiens  7 2 
Protein arginine N-
methyltransferase 1  Q99873|ANM1_HUMAN Homo sapiens  5 2 
X-ray repair cross-complementing 
protein 5  P13010|XRCC5_HUMAN Homo sapiens  4 2 
Heat shock protein HSP 90-alpha  P07900|HS90A_HUMAN Homo sapiens  3 2 
Heterogeneous nuclear 
ribonucleoprotein H  P31943|HNRH1_HUMAN Homo sapiens  5 2 
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Obg-like ATPase 1  Q9NTK5|OLA1_HUMAN Homo sapiens 4 2 
Signal recognition particle 14 kDa 
protein  P37108|SRP14_HUMAN Homo sapiens 3 2 
Coronin-1C  Q9ULV4|COR1C_HUMAN Homo sapiens 3 2 
Hemoglobin subunit alpha-3 P01935|HBA3_PANTR Pan troglodytes 3 2 
Platelet-activating factor 
acetylhydrolase IB subunit beta  P68402|PA1B2_HUMAN Homo sapiens 2 2 
Heat shock protein beta-1  P04792|HSPB1_HUMAN Homo sapiens  1 2 
Echinoderm microtubule-
associated protein-like 4  Q9HC35|EMAL4_HUMAN Homo sapiens  4 1 
40S ribosomal protein S28  P62857|RS28_HUMAN Homo sapiens  1 1 
 
 
7.5. ACTIVATION OF AKT AND ERK1/2 SIGNALLING PATHWAYS 
The next figure allows the definition of the time-points of the experiment of the 
activation of Akt and ERK1/2 signalling pathways (Figure 7.12). These results were 
obtained by Sandra Anjo during her master thesis project (unpublished data) using a 
commercially available recombinant DJ-1. 
 
 
FIGURE 7.12| TIME-COURSE PROFILE FOR THE PURCHASED RECOMBINANT DJ-1-INDUCED AKT AND 
ERK1/2 ACTIVATION IN SH-SY5Y CELLS. 
